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  ABSTRACT 
INNOVATION AND COMMERCIALIZATION PRACTICES- 
A QUALITATIVE ANALYSIS OF NOVASCAN 
 
by  
 
Shabistan Sheerin 
 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Professor Timothy B Patrick   
 
 
The processes for commercialization of medical devices in healthcare are complex and 
varied, and it has been difficult to define the ingredients of success. There exists a need to better 
understand evidence based best practices as there is lack of documented evidence based on best 
practices for commercialization of medical devices by startups. Commercialization of innovative 
medical devices in healthcare is in constant demand and the reasons are many fold. Most of the 
research based startups act as agents of economic development and therefore they need to 
function more efficiently and effectively. There exists a constant demand from end users to 
improve medical techniques, results patient experiences and cost effectiveness. However, a large 
number of strong and commercially viable innovations in healthcare fail to achieve 
commercialization. 
The purpose of this paper is to build a theory. The study examines qualitatively 
commercialization practices of case study NovaScan LLC, a breast cancer detection device 
company. Through this single case study, various performances indicators of the 
commercialization steps followed by the company are identified and findings are presented in the 
form of theoretical propositions. Extensive literature review and analysis helped in better 
understanding of the process of commercialization from both healthcare and non-healthcare 
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perspective. Data gathering, which focused on the above mentioned aim was carried on for 
nearly over four years, initially as an outsider participant and then in the latter part of study, as an 
insider participant. The data consisted of observations, informal conversations both via telephone 
and in-person, using an unstructured interview protocol, field notes, company archives and other 
historical data. Data collection participants were those institutional officials who were 
responsible both directly and indirectly for the innovation and commercialization activities at 
NovaScan LLC. All observations, conversations, field notes, documents and other records have 
been documented. The analysis for this study involves continuous back and forth linking of 
theory presented by literature findings and data obtained at NovaScan LLC. For the purpose of 
data analysis, the data is not coded sentence by sentence; rather it’s focused on theme 
identification based on underlying meaning. 
The results verify the impressions of many practitioners in the field of innovation and 
commercialization of medical devices in healthcare. The findings are presented in the form of 
seven propositions and also propose a framework of commercialization. These findings are 
recommended to be tested in future. Various activities related to commercialization process do 
not happen in isolation with product development in a startup firm like NovaScan LLC. 
Commercialization strategies are an integral part of development work and are well-aligned with 
the development process and all stages of development process overlap with each other.  
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Introduction and Background 
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1.1 Introduction 
  
 
According to Crossan and Apaydin (2000, p. 1165) “commercialization is an 
inherent part of innovation. Commercialization is said to be the least developed area of 
innovation management and that without commercialization the innovation cycle is not 
complete (Adams, Bessant & Phelps, 2006; Crossan and Apaydin, 2010). Adams et al 
(2006) actually states that this area of innovation is an urgent need of further 
development (Simula, 2012). While there is a consensus about the importance of 
innovation among scholars (Twiss, 1986; Souder, 1987; Chaney, Devinney & Winer 
Russell, 1991; Cooper, 1993; Patterson, 1998; Dodgson, 2000; Narayanan, 2001; Miller, 
2001; Debruyne et al., 2002; Pauwels, Silva-Risso, Srinivasan & Hanssens, 2004; Hsu, 
2009), there exists a lack of documented evidence based best practices for 
commercialization. 
A large number of strong and commercially viable innovations in healthcare fail 
to achieve commercialization. While innovation is incomplete without 
commercialization, commercialization is not the obvious fate of all innovations. 
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Figure 1.1 shows a broad classification of healthcare products. This dissertation is 
a qualitative, single case study directed to discovering initial evidence for best practices 
of commercialization of medical device innovations. First, the dissertation describes 
some meaningful investigative techniques to study specific commercialization practices 
and the “management” of commercialization within the context of healthcare - Medical 
Device Innovations. Second, results are described that indicate practices for a successful 
commercialization of Medical Device innovation.  
 
 
 
 
 
Healthcare Products 
Healthcare IT 
Medical Devices 
Diagnostics 
Pharmaceuticals 
Bio-tech 
(Lab and research servies) 
Therapeutics 
Figure 1.1: Broad Classification of HealthCare Products 
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1.2 Health care Industry 
 
The health care market is one of the most strongly regulated markets. Apart from 
regulations, there are several other notable differences from other products markets. 
While purchasing any other non-healthcare retail item or a service in a competitive 
market, the user is the primary customer, makes the purchasing decision, all appropriate 
information on the product is provided to the consumer with or without request, and the 
user is then the payer. However, in the healthcare marketplace, the user is often the 
patient, and in these cases usually does not make the purchasing decision. The provider 
and other intermediary institutions, such as pharmacy benefit managers make that 
decision for the user. The patient does not get all the information and the provider 
typically gets the detailed briefing and information packages. The patient is not the payer 
and usually does not know the true price of services and products. The payer is the 
insurance company or the government.  
The healthcare market is highly regulated, starting from the early product 
development stages to the preparation and dissemination of marketing information, and 
including the flow of payments, goods, and information. Manufacturers or product 
developers, therefore, need to pay attention to laws and policies as changes could affect 
their product development process. Companies must be proactive in monitoring and 
interacting with legislators (elected representatives) in government and with regulatory 
agencies. The manufacturers must monitor changes in policy that impact the market and 
take an active role to educate and inform the drafting of such policy and regulation.  
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As per the report published by National Academy of Sciences on Small 
Business Innovation and Research (SBIR), commercialization of the small businesses 
like the one chosen for the case study analysis described here are a major driver of high-
technology innovation and economic growth in the United States, generating significant 
employment, new markets and high-growth industries. In this era of globalization, 
optimizing the ability of small businesses to develop and commercialize new products is 
essential for U.S. competitiveness and it is beneficent in developing better incentives to 
spur innovative ideas, technologies, and products. (Charles W. Wessner, Editor, 
Committee for Capitalizing on Science, Technology and Innovation: An Assessment of the 
SBIR Program, Policy and Global Affairs; National Research Council of National 
Academics, Washington, D.C). 
Regina E. Herzlinger1, Professor of Business Administration at the 
Harvard Business School, identifies six forces that can drive or kill the 
innovation in healthcare sector. The first force is Industry Players: the 
friends and foes lurking in the health care system that can destroy or 
bolster an innovation’s chance of success. The second is funding which 
she describes as the processes for generating revenue and acquiring 
capital, both of which differ from those in most other industries. The third 
is Public Policy- the regulations that pervade the industry, because 
incompetent or fraudulent suppliers can do irreversible human damage. 
The fourth is technology that forms the foundation for advances in 
treatment and for innovations that can make health care delivery more 
efficient and convenient.  The fifth is customers, for whom the passive 
term “patient” seems outdated and the sixth is accountability which she 
describes is the demand from vigilant consumers and cost-pressured 
payers that innovative health care products be not only safe and effective 
but also cost-effective relative to competing products. (Harvard Business 
Review, 2006). 
1Regina E. Herzlinger (rherzlinger@hbs.edu) is the Nancy R. McPherson Professor of Business 
Administration at Harvard Business School in Boston. She is the author of “Let’s Put Consumers in 
Charge of Health Care” (HBR July 2002) and the editor of Consumer-Driven Health Care: Implications 
for Providers, Payers, and Policymakers (Jossey-Bass, 2004). She has written numerous Harvard Business 
School case studies on health care innovation, which she teaches in her course ‘Innovating in Health 
Care’. 
6 
 
1.3 Rationale for the Study 
This qualitative case study is needed for several reasons. First, a gap exists in the 
healthcare innovation and commercialization literature where there is no clear 
identification of best commercialization practices. Second, the majority of the literature 
available has tried to identify commercialization factors quantitatively and even though 
they intend to present a generalized view, they cannot be generalized with numbers 
because the innovation and commercialization practices are situation based and hence 
there is a need to evaluate and focus on the qualitative findings in order to get an in-depth 
understanding of how the practices are observed. Sapnn, Adams, Souder (1995) used 
quantitative methods to identify several factors or most frequently used factors to 
measure effectiveness of commercialization of innovations. However, their study was 
focused primarily on sponsors, developers and adopters. Previous research on federal 
transfer programs has usually focused on either the agency or departmental level 
(Souder1995).   
This single case study is based on NovaScan LLC. It explores and identifies the 
missing approach to successful practices of commercialization of innovations. It 
describes the most important metrics observed at NovaScan LLC. This may help in 
identifying differences between the most frequently adopted methods and the evidence 
based best commercialization practices.  
Another reason this study is needed is its focus on common practices of innovation and 
commercialization of medical devices in healthcare. This research will add new 
knowledge in terms of highlighting the neglected areas and provide detailed information 
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on bringing innovations from bench to bedside in a more successful and viable way. 
Finally, this study may help the future researchers to explore the process of 
commercialization in other areas of healthcare products in different organizational 
settings.  
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1.4 Research Questions 
The overall main research question is: What practices can be identified as the 
best practices engaged in the process of commercialization of a medical device 
innovation?  
To answer this main question, it’s necessary to answer the following questions in regards 
to the case study 
R1: What activities did technology innovators and researchers perform at NovaScan 
to initiate the process of commercialization?  
R2: What is the evidence that these approaches are successful? 
Any answers to these above mentioned questions presuppose answers to the questions 
like: what is product innovation? What is commercialization? What defines success and 
failure in innovation and how are they measured? The answers to most of these questions 
were found in the literature analysis and guided me to find answers to the main research 
question.  
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1.5 Structure of the Dissertation 
Chapter one provides background to the dissertation. The objectives and scope are 
introduced together with the research questions. There is also a brief discussion of the 
overall structure of the dissertation. Appendix A includes definitions of key terms. 
Chapter two reports results of the literature review. The literature search, selection 
and review methods are discussed. How the method helped me identify core areas and 
themes around were also discussed. These helped in the data analysis of this dissertation. 
 Chapter three focusses mainly on the research method and description of the data 
source and collection. The discussion provides insights as to why qualitative research and 
analysis method was chosen for this dissertation. In addition a detailed analysis of 
selection of case study research method and also reasons to why a quantitative scheme 
would not have worked in the study situation are provided. 
Chapter four focusses on the findings of the research. This will include the results 
obtained by data analysis and literature analysis. This chapter shares details about the 
case study firm and describes the operational concept of this case study and the strategic 
commercialization strategy.  This part of dissertation focusses on theory for 
commercialization and continues with the within case analysis. 
Chapter five includes propositions that are based on the research findings 
discussed in chapter four. The propositions are derived from the analysis of the case 
study, but they are also combined with insights derived from the literature. 
10 
 
 Chapter six describes the overall conclusion to this study. It describes how the 
dissertation contributes to commercialization theory of healthcare innovations and also 
outlines several related implications. Also discussed are the validity, reliability, and 
limitations of the study in this chapter and finally, suggestions for future research are 
made here in this chapter. 
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Chapter 2 
Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
This chapter reports results of review and analysis of voluminous, 
multidisciplinary literature on innovation, commercialization and technology transfer. 
Technology transfer is the common link that connects innovations and commercialization 
processes. The selection of literature was based on the main research question that aims 
at identifying successful practices of commercializing a medical device innovation. 
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2.1 Methods 
The main research question for this dissertation is: What practices can be 
identified as the best practices engaged in the process of commercialization of a 
medical device innovation?  This helps in getting answers to the following questions. 
R1: What activities did technology innovators and researchers perform at NovaScan 
to initiate the process of commercialization?  
R2: What is the evidence that these approaches are successful? 
 
Bosewell and Cannon (2010) in their book, Introduction to Nursing Research: 
Incorporating Evidence based Practice (2010) state that there are two methods of 
searching literature- performing computer search in databases and examining books and 
periodicals manually. While searching for literature based on the main research question, 
healthcare specific databases like Cochran and Medline were looked at and then some of 
the business and management databases were searched for innovation and 
commercialization.  
After searching various databases, only a small number of relevant publications 
were found. However, the databases did oint towards some of the leading journals. This 
helped in searching more specifically in their local journal database. Along with these the 
university based search database system was also used. The electronic search ended in 
manual search where direct search with the relevant journals was conducted, Allowing 
14 
 
article linking through citations. Out of several articles, the articles that were more 
specific to innovations and commercialization in healthcare first and then the process of 
commercialization, innovation and technology transfer more specifically were chosen. 
The articles were not short listed on the basis of key-words. Rather, a more specific 
relevance by reading through abstracts and then sometimes the whole article was used. In 
conducting the literature search it is important to keep a record of the keywords and 
methods used in searching the literature as these will be used later when describing how 
the search was conducted (Timmins and McCabe, 2005). 
The search included key terms as healthcare innovations, commercialization, 
technology transfer, success of innovations and commercialization best practices and so 
on. Literature search on published material since 1980 was conducted. However, it was 
found that literature published in last ten to fifteen years were more appropriate for 
analysis. Apart from these, some relevant literature published prior to 1980’s were also 
used.  
To reduce the literature to manageable proportions, the literature findings were 
divided into three main themes-(1) innovation, (2) Technology Transfer and (3) 
commercialization. The extant literature is reviewed and synthesized to uncover the key 
emerging themes and to build a framework based on those themes. Since 
commercialization of innovation serves interest to a multitude of disciplines including 
management, marketing, entrepreneurship, economics, and other multidisciplinary 
domains, this literature review captures a more comprehensive view across fields. The 
shortlisted articles rather than just the abstracts were searched for these three themes.  
15 
 
After removing the overlapping articles from the databases, 90 articles were 
shortlisted based on the focus exclusively on literature on Innovation and 
commercialization, from 33 journals across the disciplines of management, strategy, 
entrepreneurship, economics, and marketing (See Appendix A(a) and A(b)). In terms of 
distribution of articles across themes, it is worth noting that several articles corresponded 
to more than one theme. 
A set of fundamental conceptual issues, especially the models surrounding 
innovation in general and with respect to healthcare in particular were examined. Along 
with the published journal articles, some relevant textbooks, website published articles, 
blogs and other materials were also used for a detailed analysis. 
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2.2  Innovation 
Innovations are important for technological progress and overall economy and 
growth in business. They extend our technological capabilities and improve productivity, 
and also contribute to the wealth of society and high standards of living (Simula 2012). 
Innovations also increase market share and contribute to the comparative and absolute 
advantages of a firm (Twiss, 1986; Souder, 1987; Patterson, 1998; Dodgson, 2000; 
Narayanan, 2001; Simula, 2012). 
One of the main issues when discussing the term “innovation” has been its liberal usage 
by its practitioners. The literature in academia also suffers the same problem. There are 
often various, different extensions attributed to “innovation”. To clarify this issue in this 
section, apart from discussing innovations as a process, this section also describes 
innovations from the healthcare perspective. 
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2.3 Definition of Innovation 
The word innovation has its origins in the Latin word “innovare,” which can be 
translated as “to re-new, to make, or to alter” (Souder, 1987; Narayanan, 2001). 
Innovation can be defined as the intentional introduction and application within a role, 
group, or organization, of ideas, processes, products or procedures, new to the relevant 
unit of adoption, designed to significantly benefit the individual, a group, or wider 
society(West, 1990). This definition is largely accepted among researchers in the field of 
innovation (Anderson, et al., 2004), as it captures the three most important characteristics 
of innovation: (a) novelty, (b) an application component and (c) an intended benefit 
(Lansisalmi, et al., 2006).   
According to Zaltman, Duncan, and Holbek (1973), innovations can be discussed 
in three different contexts: (1) innovations can refer to an invention and the creative 
process itself; (2) innovations can refer to the adoption process; and (3) innovations can 
refer to “..that idea, practice, or material artifact that has been invented or that is regarded 
as novel independent of its adoption or non-adoption” (ibid., p. 8).  
Innovation as defined by United Nations Educational, Scientific and Cultural 
Organization (UNESCO) is the implementation of a new or significantly improved 
product (goods or service), or process, a new marketing method or a new organizational 
method in business practices, workplace organization or external relations (UNESCO 
Institute for Statistics, 2005).The chart below shows the different classification of 
innovations defined by UNESCO (Table 2.1). 
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• Introduction of a good or service that is new or significantly improved with respect to its 
characteristics or intended uses. This includes significant improvements in technical 
specifications, components and materials, incorporated software, user friendliness or 
other functional characteristics. 
Product Innovation 
• Implementation of a new or significantly improved production or delivery method. This 
includes significant changes in techniques, equipment and/or software. The customer 
does not usually pay directly for process, but the process is required to deliver a product 
or service and to manage the relationship with the various stakeholders. 
Process Innovation 
• Implementation of a new marketing method involving significant changes in product 
design or packaging, product placement, product promotion or pricing. 
Marketing Innovation 
• Implementation of a new organizational method in the firm’s business practices, 
workplace organization or external relations. 
Organizational Innovation 
Table 2.1 Innovation as defined by UNESCO 
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There’s also a debate on differences between invention and innovation. 
Inventions and innovations are often confused. Schumpeter (1939) describes that 
innovations are inventions that are commercialized in the market by entrepreneurs. 
According to Smith (2006), commercialization is required before an invention can 
become an innovation. He also notes that in reality, many inventions will never turn out 
to be innovations. Many authors have tried to define innovation. Table 2.2 lists various 
definitions in the field of innovation (Souder, 1987). Please see Appendix B for more 
definitions of innovations. While the collection of definitions is not collectively 
exhaustive, it does highlight the vagueness of innovation terminology in literature.  
 
 
 
Table 2.2 Various definitions in the field of innovation (Souder, 1987) 
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2.4 Innovation in Healthcare 
Innovation in healthcare can be defined as the introduction of a new 
concept, idea, service, process, or product aimed at improving treatment, 
diagnosis, education, outreach, prevention and research, and with the 
long term goals of improving quality, safety, outcomes, efficiency and cost 
(Omachonu 2010). 
 
 
The process of innovation is both complex and multi-dimensional regardless of 
the industry in which it is being applied. Innovation in the healthcare industry has its 
own unique challenges. Any attempt to understand the process of innovation in 
healthcare must begin with an in-depth analysis of its challenges. There are five key 
stakeholders in the innovation process (Omachonu 2010), and each has its unique and 
deliberate needs, wants and expectations as shown in Table 2.3. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3 Stakeholders in the process of healthcare innovations and their expectations 
 Source: Omachonu 2010 
 
 
It has been suggested that it is difficult to change the behavior of clinicians 
(Greco and Eisenberg, 1993), current medical practices, and healthcare organizations 
Stake Holders Needs, Wants & Expectations 
Physicians and Other 
Care Givers 
Improved clinical outcomes, improved diagnosis and 
treatment 
Patients Improved patients’ experience, improved 
physiological well-being, reduced waiting time, reduced delay 
Organizations Enhanced efficiency of internal operations, cost 
containment, increased productivity and quality and outcomes 
improvement 
Innovator Companies Profitability, improved outcomes 
Regulatory Agencies Reduced risks and improved patient safety 
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(Shortell, Bennett, and Byck, 1998; Shortell et al., 2001) ( Litaker et al.,2006). The 
adoption of healthcare innovations is often regulated by laws, making changes more 
laborious (Faulkner and Kent, 2001). In healthcare, typical starting points of an 
innovation process may lead to death, disability, or permanent discomfort (Lansisalmi, 
et al., 2006). This, together with the clinicians’ tendencies to protect their individual 
autonomy and reputation, can promote a culture of blame and secrecy that inhibits 
organizational learning and the generation of innovations (Huntington, Gilliam and 
Rosen, 2000). Furthermore, new practices in patient care are traditionally scrutinized 
thoroughly in their early development phase so that potentially harmful innovations are 
not adopted (Faulkner and Kent, 2001).  
Any attempt at modeling the process of health care innovation must take into 
account the key stakeholders as shown in Figure 2.1 (Omachonu & Einspurch, 2010). 
Healthcare organizations serve six distinct purposes – treatment, diagnosis, prevention, 
education, research and outreach. In serving these purposes, other parameters that 
healthcare organizations must effectively manage are quality, costs, safety, efficiency 
and outcomes. At the very core of healthcare innovation are the needs of patients and 
the healthcare practitioners and providers who deliver care. 
 
 
 
22 
 
 
Figure 2.1: Framework of healthcare innovation (Adapted and modified from Omachonu 2010) 
 
Quite often, healthcare organizations arrive at innovation by relying on new or 
existing information technology. When successful, healthcare innovation focuses on the 
following three areas the most –  
a) How the patient is seen,  
b) How the patient is heard, and  
c) How the patient’s needs are met (Omachonu 2010) (Figure 2.1). 
Innovations in healthcare have mostly been stimulated by the patients, 
healthcare organizations, researchers, physicians, and other healthcare professionals. In 
some cases, the need for change is forced upon the healthcare organizations by the 
federal agencies to alleviate healthcare concerns and challenges or by market 
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Patient  Providers 
Purpose Parameters 
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competitors. Sometimes the need arises from within the healthcare system. Once the 
need is identified, the next challenge is to identify procedures of innovation and then it 
is tested, modified and adopted. On some occasions, for example, a healthcare 
technology company can develop, test and later market the innovative technology to 
healthcare organizations. In certain cases, a healthcare innovation company takes what 
might be an imperfect attempt at innovation from a healthcare organization and refines 
it into a better product, and then markets it to healthcare organizations. 
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2.5 Innovation Process Models 
There are various innovation models that help firms to create innovations. These 
models have evolved over the course of time. The main reason for this change is the 
change in the environment in which innovation takes place (Rothwell 1994). The 
models discussed here in this section have been found mostly from management books 
and scientific journals. 
 
According to Professor Joe Tidd of University of Sussex, describes that the early 
innovation models define innovation as a linear sequence of functional activities.  
 
He says, “either new opportunities arising out of research give rise 
to applications and refinements which eventually found their way to the 
marketplace (‘technology push’), or else the market signaled needs for 
something new which then drew out new solutions to the problem (‘need 
pull’, where necessity becomes the mother of invention). However, in real 
practice successful innovations exist as a combination and interaction of 
both technology pull and technology push phenomenon”. (Review of 
innovation models, Imperial College of London 2006). 
 
 
Roy Rothwell, a key researcher in the field of innovation management 
suggested that the innovation process has evolved from simple linear models 
(characteristic of the 1960s) to increasingly complex interactive models (Figure 2.2). 
His first generation model stresses technology pull and technology push methods 
whereas the fifth generation model treats innovation as a more complex, multi-actor 
process, which requires high levels of integration. 
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According to the technology-push model, the source of new discoveries are 
within the research and development team and are iterated, modified and eventually 
applied to products that are left for marketers to promote to potential customers. 
Technology push assumes that there is a need in the market that requires innovation. 
So, the customer and market needs are the starting points and initiators for new ideas 
and requirements and research has more of a reactive role in finding solutions to 
emerging needs. This constitutes the first and second model suggested by Rothwell. 
The third-generation model highlights the coupling of functional entities and suggests 
that innovations are the result of knowledge between research and development, 
marketing and manufacturing being shared. The interactive, or integrated, model 
represents the fourth level of innovation and it considers a firm’s activities to occur 
parallel to one another. This model acknowledges that innovation occurs or originates 
First and 
Second 
•The linear models – 
need pull and 
technology push 
Third 
•Interaction between 
different elements and 
feedback loops 
between them – the 
coupling model 
Fourth 
•The parallel lines 
model, integration 
within the firm, 
upstream with key 
suppliers and 
downstream with 
demanding and active 
customers, emphasis 
on linkages and 
alliances 
Fifth 
•Systems integration 
and extensive 
networking, flexible 
and customized 
response, continuous 
innovation 
Figure 2.2: Rothwell’s five generations of innovation models: Listing generation and its key features 
Source: Adapted from Tidd, Bessant and Pavitt, 2005, 
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from different points as a result of concurrent tasks. Finally, the fifth-generation, 
innovation-process model is a complex set of communication paths and systems 
integration with strong external networking (Dodgson & Rothwell, 1994; Trott, 2002; 
Simula 2012). 
Cooper (1968) introduced the stage-gate process with distinctive and orderly 
phases. He prescribed that a given phase can only start if the project satisfied all earlier 
requirements. This is not only useful to determine if the project should proceed or not, 
but also to keep track of possible new occurrences during the process. Hartley (2006) 
argues stages are helpful for conceptualizing the innovation process and determining 
where drivers and barriers can occur. 
Tidd and Bessant (2005) and Jacobs and Snijder (2008) adopted the stage-gate 
model of Cooper in the implementation phase of their model. During the first phases of 
idea generation and selection, the phases are less linear and have more feedback loops, 
while in the later phases, they recommend a more formal and rigid process. 
All models start with some form of idea generation or searching for ideas for 
innovation (Eveleen 2010). Some authors emphasize the openness and acceptance 
(Nooteboom 2001, Mulgan and Albury 2003, Jacobs and Snijders 2008) and some 
argue that this is considered to be divergent behavior (Van der Ven et al., 1999). 
The next step is to narrow the options down, to make a decision, and to select 
projects to be purused or not to be pursued (Rogers 1962, Nooteboom 2001, Tidd and 
Bessant 2005, Jacobs and Snijders 2008). This selection should be based on both the 
organizational strategy and on the existing portfolio. At this point it has to be judged if 
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the innovation is potentially lucrative enough (Andrews and Sirkin 2006) and if it is 
going to increase public value enough (Moore 1995).  
The next step is to turn the (selected) idea into some tangible product, process or 
service (Eveleen 2010). To describe this process, words such as development (Cooper 
and Kleinschmidt 1986, Van der Ven et al.1999 and Verloop 2004), prototyping  
Mulgan and Albury 2003),  manufacturing (Rothwell 1994) and realization (Andrews 
and Sirkin 2006, Jacobs and Snijder 2008) are used. Most commonly this phase is 
known as development and testing phase. 
The fourth general step is implementation of newly developed technology or 
product. Implementation impliers put to work in real word. This phase is called 
implementation/launch. It entails the preparing of customers and marketing activities. 
Most authors stop here with their innovation process.  
However, some authors (Rogers 1962, Nooteboom 2001, Mulgan and Albury 
2003, Tidd and Bessant 2005 and Jacobs and Snijders 2008) include a post launch 
phase. This entails the sustaining and supporting of the innovation or even re-
innovating it and scaling it up. Finally, Mulgan and Albury (2003), Tidd and Bessant 
(2005) and Jacobs and Snijders (2008), include a phase for feedback. It helps in not 
only learning about the innovation itself, but also about how the innovation process 
went. This stage prevents future mistakes and product/technology improvisation. 
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2.6 Innovation as a Non-Integrated Process 
Table 2.4 provides an overview of the difficulties that arise if we take a partial view 
of innovation (Tidd et al, 200).  
 
Innovation Process Results  
Strong R&D capability Technology which fails to meet user needs and may 
not be accepted 
The province of specialists Lack of involvement by others and a lack of key 
knowledge and experience input from other 
perspectives in the R&D 
Understanding and meeting customer needs Lack of technical progression, leading to inability to 
gain competitive edge 
Advances along the technology frontier Producing products or services which the market does 
not want or designing processes which do not meet 
the needs of the user and whose implementation is 
resisted 
The province only of large firms Weak small firms with too high a dependence on 
large customers. Disruptive innovation as apparently 
insignificant small players seize new technical or 
market opportunities 
Only about ‘breakthrough’ changes Neglect of the potential of incremental innovation: 
with an inability to secure and reinforce the 
gains from radical change because the incremental 
performance ratchet is not working well 
Only about strategically targeted projects May miss out on lucky ‘accidents’ which open up 
new possibilities 
Only associated with key individuals Failure to utilize the creativity of the remainder of 
employees, and to secure their inputs and perspectives 
to improve  innovation 
Only internally generated The ‘not invented here’ effect, where 
good ideas from outside are resisted 
or rejected 
Only externally generated  
 
Innovation becomes simply a matter of filling a 
shopping list of needs from outside and there is little 
internal learning or development of technological 
competence 
Only concerning single firms  
 
Excludes the possibility of various forms of inter-
organizational networking to create new products, 
streamline shared processes, etc. 
Table 2.4: Type of innovation processes and its results  
(Source: Adapted from Tidd, Bessant and Pavitt, 2005; Tidd, 2010) 
 
Brandbury (1989) also presents an innovation-project model with four phases: 
(1) Feasibility, (2) Applications, (3) Development and (4) Exploitation. He suggests 
through this model that first phase is base product innovation and evaluation followed 
by its consolidation, application product innovation, and evaluation. Then comes the 
product (may include process as well) development and evaluation leading to its 
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strategy and data selection, patenting and consultancy, proposal, presentation and 
negotiation for project adoption (Simula 2012).  
Rogers (2003) describes the same innovation process as a series of stages and 
says that the order of stages may change and that some of the stages can be omitted in 
certain cases; he also admits that many innovations deviate from this general process 
flow. 
Simula (2012) in a detailed literature review of innovation processes states that 
Koen et al. (2001) present a similar linear model, in which they divide the innovation 
process into three phases, i.e. a front-end phase, a new product development phase, and 
a commercialization phase whereas Padmore, Schuetze, and Gibson (1998) also refer to 
linear and chain-link models, they ultimately introduce a more cyclical model. Also, 
Schoen, Mason, Kline, and Bunch (2005) have criticized linear models and propose a 
cyclical model for innovation development.  
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2.7 Sources of Innovation 
 
There exists a significant amount of literature on sources of innovation but there 
is no widely recognized theory exists that provides an exact answer regarding the 
origins of innovations. Innovation research have been inconclusive, inconsistent, and 
characterized by low levels of explanation (Bigoness and Perreault, 1981; Damanpour, 
1988; Downs and Mohr, 1976; Kimberly and Evanisko, 1981; Nord and Tucker, 1987; 
Pennings, 1987; Rogers, 1983). Chaston (2000) illustrates entrepreneurial approach to 
innovations where the key question to start with is “why not? (Simula 2012) Sheth and 
Ram (1987) identify four distinct forces responsible for the increasing importance of 
product and service innovation for organizational survival in the 1990s.  
These provide a useful framework for considering drivers for innovation and, 
are presented in Figure 2.3. These factors driving innovation are intricate and 
interwoven. Another factor that can be identified as a source of Innovation is firm size. 
Schumpeter (1939) has suggested that the size of a firm matters and, thus, that larger 
firms are more innovative. His argument is grounded in the idea that larger firms have 
Changes in 
operating 
environment 
Technological 
changes 
Customer 
Changes 
Changing 
nature of 
competition 
Technological 
changes 
Figure2.3: Forces driving innovation (Source: adapted from Sheth & Ram 1987) 
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more financial and organizational resources, risk tolerance, and economies of scale for 
R&D projects and, thus, more chances to provide for more innovation (Simula 2012). 
However, Narayanan (2001) argues differently. According to Cyert and March (1992), 
successful firms are the ones that lead to more innovations as they have the required 
essential funds for innovations. However, Cyert and March (1992) also state that 
unsuccessful firms can create innovations when they are forced to solve acute problems 
that they are facing. Palmberg (2004) states that variables of customer demands, market 
niches, and collaboration with customers that give birth to innovations.  
 
 
 
 
Similarly, new management ideas can lead to overcome the trade-offs between 
efficiency and profitability (Magnusson & Martini, 2008) and provides a basis for new 
innovations (Simula 2012). Figure 2.4 is taken from the book “101 Design Methods: A 
Structured Approach for Driving Innovation in Your Organization” written by 
Professor Vijay Kumar at University of Illinois. He describes the forces behind 
Figure 2.4: A Structured Approach for driving innovations in an organization 
(Source “101 Design Methods) 
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innovation are society, needs business and technology. Any of these factors when lay 
open to change, might become a reason of innovation (Figure 2.4). 
The innovation process (Dosi 1988) is the result of complex activity and it 
requires a combination of several elements, internal and external to the firm: indeed, it 
is important to consider not only the organizational and managerial capabilities of 
individual companies, their investment or the size of the firm, but it is important to 
consider also a series of external elements, such as the collaboration with other firms or 
with universities that can improve the internal activity.  
Amore and Iorio in a detailed literature analysis of various innovation sources 
describe that common strand all over the literature on firm strategy and performance is 
the diffuse utilization of strategic alliances or collaboration at all steps of the innovation 
process to accelerate innovative activities (Audretsch, 2001; Bagchi-Sen 2004; 
Terziovsky and Morgan, 2006). In this way firms can improve their competitiveness 
position by integrating technology in the innovation process and facilitating intra and 
inter firm knowledge and technology transfer (Amir-Aslani and Negassi, 2006; Boer et 
al, 2001; D’Amore,R. and Iorio, R.). Deeds and Hill (1996), Freeman (1991), 
Hagedoorn (1995) analyzed the topic of the relation between firm’s rate of new product 
development and the number of strategic alliances and they concluded that higher levels 
of expenditures in R&D and scientific ingenuity are positively correlated with higher 
levels of collaboration. Internal capability and external collaboration have been found 
to be complements rather than substitutes (Arora and Gambardella 1994; Pisano et al, 
1988; Rothaemel, 2001). In particular, Pisano at al., (1988) studied the relationship 
between in-house R&D and collaboration and they found the two to be complementary, 
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as in-house R&D capability attracts collaborative partners. Shan et al., (1994) examined 
the relationship between the number of collaborators and innovative output. They 
conclude that, while collaboration advances innovation, innovation does not necessarily 
require collaboration. Schumpeter (1942) as discussed earlier in this section, argued 
that innovation activity is promoted by large firms on a large scale, Jexkes, Sawers and 
Stillerman (1958) demonstrated that most inventions arose from individuals or small 
groups. 
Mueller (1962), showed that the major part innovations originated from smaller 
firm or individuals. According to Damanpour(1992) a smaller firm might be more 
innovative because of flexibility and ability to accept and effect the change than in a 
large firm. Kamien and Schwartz (1982) describe that smaller firms are more motivated 
to innovations as there is a visible impact on the firm’s overall performance. 
Another source of innovation can be a firm’s number of patents. Bound et 
al.(1984) demonstrated that the number of patents increases at a rate that is less than 
proportional to firm size and other authors; Acs and Audretsch (1987, 1991), confirm 
the same results using the number of innovation as an output variable. 
Halperin and Chakrabarti, (1987) use the number of a firms scientific 
publications as source of innovation. Henderson and Cockburn (1996), Mansfield, 
(1980) showed that larger firms have in some cases an advantage in innovation. There 
can be several factors that can influence innovation performance. 
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2.8 Technology Transfer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Technology Transfer Process 
 
Mansfield (1975) pointed out that, “One of the fundamental processes that 
influence the economic performance of nations and firms is technology transfer.” 
Technology transfer (TT) is an area of interest not just to business, economists, and 
technologists but also to other disciplines such as anthropology and sociology (Zhao 
and Reisman, 1992). For economists, as argued by Mansfield (1975), the focus is on 
economic growth and achievement of economic goals.  
However, from the perspective of business and technologists the main focus of 
TT is to improve the competitive advantage of firms through the enhancement of 
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customer value (Ramanathan, 2001). Even though technology transfer is not a new 
business phenomenon, the considerable literature on technology transfer that has 
emerged over the years agrees that defining technology transfer is difficult due to the 
complexity of the technology transfer process (Robinson 1988; Spivey et al.1997). The 
definitions depend on how the user defines technology and in what context (Chen 1996; 
Bozeman 2000).  
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2.9 Definition of Technology Transfer 
 
The term technology transfer can be defined as the process of movement of 
technology from one entity to another (Souder et al.1990; Ramanathan 1994). The 
movement may involve physical assets, know-how, and technical knowledge 
(Bozeman, 2000). Technology transfer in some situations may be confined to the 
relocating and exchanging of personnel (Osman-Gani 1999) or to the movement of a 
specific set of capabilities (Lundquist 2003). 
Technology transfer has also been used to refer to movements of technology 
from the laboratory to industry, developed to developing countries, or from one 
application to another domain (Philips 2002) (Ramanathan 1994). Gibson and Rogers 
(1994) defined technology transfer as application of information, in a regulating sense 
where technology is considered as information.  
In an analogous disposition economists Arrow (1969) and Dosi (1988) analyzed 
technology transfer on the basis of the properties of generic knowledge, focusing 
particularly on variables that relate to product design. Mittleman and Pasha (1997) have 
attempted a broader definition where they state that technology transfer is the 
movement of knowledge, skill, organization, values and capital from the point of 
generation to the site of adaptation and application. 
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2.10 Technology Transfer Models 
 
 
Since the early 1970s, considering the difficulties and complexities faced by 
managers of technology transfer projects, researchers, consultants, and practitioners of 
technology transfer have been proposing models of technology transfer that could 
facilitate the effective planning and implementation of technology transfer projects 
(Ramanathan 2010). Here in this section some of the models proposed from qualitative 
perspective are discussed. According to Ramanathan in his article “An overview of 
technology transfer and technology transfer (TT) models”, Jagoda (2007) points out 
that,  
“Qualitative models often have as their objective the delineation of 
activities involved in managing TT and the elicitation of factors and issues 
that can influence the success and/or effectiveness of TT. Quantitative 
models, on the other hand, aim at quantifying parameters of significance 
in TT and analyzing them with a view towards minimizing goal 
incompatibility between the transferors and transferees of 
technology”(Jagoda 2007). 
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2.11 A Brief Overview of Some Qualitative and Quantitative TT Models 
 
(a) The Bar-Zakay Model: Based on a project management approach, a comprehensive 
TT model is offered by Bar-Zakay (1970). He divided the TT process into the Search, 
Adaptation, Implementation, and Maintenance stages. He depicted the activities, 
milestones, and decision points (go or no-go) in each of these stages as shown in Figure 
2.6. The upper half of the figure delineates the activities and requirements of the 
transferor (referred to as the “donor” by Bar-Zakay) and the lower half that of the 
transferee or the “recipient.” The model uses the term “donor” for the transferor giving 
the impression that the owner of technology is giving away a valuable asset out of 
altruistic reasons! This is clearly not the case and the use of such terms must be 
avoided.  
The Bar-Zakay model also suffers from another disadvantage. Jagoda (2007) 
points out that,  
“The model has limited relevance today since many of the activities, 
terms, and ideas expressed reflected the setting of the late 1960s to early 
1970s, when buyers of technology were mainly passive recipients who 
depended greatly on aid programs for the purchase of technology. It was 
also an era when government controls were instrumental in determining 
the rate, direction, and scope of technology flows” Jagoda (2007). 
(b) The Behrman and Wallender Model: Behrman and Wallender (1976) have 
proposed a seven stage- process for international technology transfer that may be 
more relevant to multinational corporations. Some of the features of this model are 
following: 
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Figure 2.6 The Bar-Zakay model of technology (1970) 
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• There is a need for the transferee to be involved right from the beginning in 
the planning and implementation of a TT project. 
• TT project does not end with commencement of production. 
• Unless explicit measures are in place to ensure assimilation of the transferred 
technology, the TT cannot be said to have been successful. 
 
 (c) The Dahlman and Westphal Model:  Dahlman and Westphal (1981) carried 
out considerable work in the Republic of Korea and, based on their experience in 
rapidly industrializing countries during the 1980s, proposed a nine stage process 
model. However, this model may be regarded as an improvement of the Behrman 
and Wallender model with great emphasis on transferee involvement at all stages 
of the technology transfer project. The important lessons that this model presents 
include the following: 
• A TT project is best studied using a sequential process perspective. 
• Any TT project should not be commenced without a careful feasibility 
study since such projects often require heavy resource commitments. 
• The transferee should be involved in the planning right from the beginning. 
• It is important for transferees to develop sound engineering and project 
management skills without which the TT process cannot be managed 
effectively. 
(d)  The Schlie, Radnor, and Wad Model:  Schlie et al. (1987) proposed a simple, 
generic model that delineates seven elements that can influence the planning, 
implementation, and eventual success of any TT project.  
The valuable lessons that emerge from this model are as follows: 
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• The many changes that have taken place and are taking place in the 
global business setting today have made it imperative for managers of 
technology to gain good insights into the transferee environment, transferor 
environment, and the greater environment when planning and 
implementing a TT project. 
• The choice of the technology transfer mechanism should be based on a 
sophisticated understanding of the other six elements. 
 
    
(e) The Chantramonklasri Model: The Dahlman and Westphal Model has been 
further improved by Chantramonklasri (1990 who proposes a five phase model as 
shown in Figure2.7. 
The five phases of this model are as follows: 
• Carrying out a pre-investment and feasibility study 
• Developing engineering specifications and design based on the feasibility study 
Figure 2 .7  The five-phase model of international 
technology transfer. (Source: Jagoda 2007) 
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• Commence capital goods production based on the engineering specifications 
and designs that have been developed. 
• Commissioning and start-u including comprehensive of the workforce 
• Commence commercial production 
As in the Dahlman and Westphal Model, the negotiation and assimilation elements 
are missing from this model as well. The lessons that may be learned in this case are 
similar to those of the Dahlman and Westphal Model. 
(f) Other Qualitative Models of TT: There are several other models that have been 
developed. However, these will only be described briefly. Lee et al. (1988) have 
developed a longitudinal model of technology transfer based on a study of 
developing and rapidly industrializing countries. They point out that a transferee 
firm needs to put in place strategies to be  able  to  go  through  the  stages  of  
acquisition,  assimilation,  and  eventual  improvement.  As the firm advances 
technologically, it needs to choose appropriate mechanisms of transfer, depending on 
the stage of the life cycle of the technology and their own technological capability 
profile. They also note that the mechanisms chosen by the transferor to transfer 
technology will depend on the relative newness of the technology, its strategic 
importance to the transferor firm, and the level of intellectual property protection 
needed. 
Reddy and Zhao (1990), in a model similar to that of Schlie et al. (1987) 
state that any international technology transfer (ITT) project should examine three 
main components, which they refer to as the home- country component, host-country 
component, and transaction component. The home country is that of the transferor and 
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the host country is that of the transferee. The transaction component consists of 
important business issues such as the pricing of technology, intellectual property 
protection, payment modalities, potential conflicts, and measures for ensuring 
effective transfer. 
Keller and Chinta (1990) argue that effective TT would be determined by the 
extent to which the transferor and transferee manage the barriers that impede transfer 
and strengthen initiatives that facilitate it. The facilitating initiatives refer to the 
willingness of the partners to adapt their respective strategic and operational postures 
to ensure a “win-win” outcome. The barriers could be political, legal, social, 
cultural, economic and technological. They also stress the importance of selecting the 
correct mechanism to transfer the technology. 
The United Nations Industrial Development Organization (UNIDO) (1996) 
model, in what appears to be an endorsement of the Bar-Zakay approach, suggests 
that, in the manufacturing  sector, once the need for a TT project is established,  the 
steps of search, evaluation, negotiation, contract execution, and technology 
adaptation and absorption should be followed sequentially to ensure effectiveness. 
 Durrani et al. (1998) proposed a generic model (Figure 2.8) consisting of five steps: 
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Figure 2.8: Technology transfer model, Source Durrani et al. 
 
 
This model stops with the technology acquisition decision. Its major lesson is 
that it stresses the importance of establishing the need for a TT project and the need 
for identifying multiple sources of technology for enabling a better choice of 
transferor. 
Bozeman (2000) has proposed a contingent effectiveness model of TT. While 
the emphasis is on technology transfer from universities and government laboratories 
to industry, the model is also relevant to inter-firm TT. This model also stresses o n  
importance of establishing the need for a TT project and the need for identifying 
multiple sources of technology for enabling a better choice of transferor. Six “out-
the-door” measures are proposed. These are market impact, economic development, 
political benefits, opportunity assessment is a valuable lesson that this model imparts. 
(g)  A Brief Overview of Some Quantitative TT Models: The literature is sparse 
when it comes to quantitative models of technology transfer. Some of the more 
Establishing market-
place requirements 
Identifying 
technology 
solutions 
Classifying 
the 
identified 
technology 
solutions 
Establishing 
sources from 
where the 
desired 
technology 
could be 
acquired 
Finalizing 
the 
technology-
acquisition 
decision 
45 
 
important models are described briefly. T he interested reader may wish to refer to 
the original publications if further information is sought. 
Perhaps the earliest quantitative model is due to Sharif and Haq (1980). This 
model proposes the concept of potential technological distance (PTD) between a 
transferor and transferee and argues that when the PTD is either too great or too 
small between the transferor and transferee, the effectiveness of the transfer is low. 
It suggests that when a transferee first looks for a potential transferor it is important 
to look for one with an “optimal” PTD. From a practical point of view, a potential 
transferor at the firm level may not be willing to easily divulge information that 
could enable an assessment of the PTD. The greatest value of the model is that it 
draws attention to the need for incorporating the concept of a PTD in deciding the 
transferor. 
Raz et al. (1983) have presented a model of technological “catch-up” that 
shows how a technology leader, through technology transfer, can assist the rate of 
technological development of a technology follower. The model examines three 
phases of growth of a technology follower namely, the slow initial phase with high 
technological capability gap, the faster learning phase with the decreasing gap, and 
the catch-up phase when the technological gap is very small or closed. They argues 
that this type of analysis would enable technology leaders  to develop  clear 
policies,  based on considerations  of competitiveness,  security,  and other related 
issues, when entering into TT agreements. 
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It may be said that the main contribution of the quantitative models is their 
emphasis on the need for partners in TT projects to develop skills and approaches for 
better TT planning. 
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2.12 Laws of Technology Transfer 
The transfer of new technology from university laboratories to the private sector 
has a long history and has taken many different forms.  The current national emphasis 
on this activity, however, can be dated to the 1980 enactment of P.L. 96-517, The 
Patent and Trademark Law Amendments Act, more commonly known as the Bayh-
Dole Act. Appendix C lists the various laws and their inclusions exclusive for TT and 
applicable to across technological innovations.  
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2.13 Commercialization 
 
Academic researchers have used innovation and commercialization in the same 
construct however with the difference in the processes of the two; the two definitions 
became rather distinct. For a company to be successful, continuous innovations are 
almost necessary however it is not necessary that every innovation becomes a 
successful commercialization. 
Commercialization is defined as the act or activities required for introducing an 
innovation to the market (Andrew & Sirkin, 2003; Kelm, Narayanan, & Pinches, 1995; 
Kwak, 2002; Nambisan & Sawhney, 2007; Narayanan, Pinches, Kelm, & Lander, 2000; 
Nerkar & Shane, 2007). To commercialize an innovation we is to bring a product into a 
market and reach the mainstream of the market further than the innovators. 
Cooper (1993) defined commercialization as “‘the ‘back end’ of the process, 
including market launch, production start-up, trial sell, and production”. According to 
Rogers (2003), commercialization can be seen also as “The conversion of an idea from 
research into a product or service for sale in the market place”. There is no generic form 
of commercialization and therefore there is a fundamental difference between the 
commercialization of technology and the commercialization of products. 
 Jolly (1997) provides a good distinction between these two by stating that, 
 A technology is essentially a “capability”, often a versatile one that can be 
used in more than one product. Products are occasional embodiments of 
this capability and mediate the process of bringing it to market and 
realizing from it. These technology and products, however often have 
separate existences, following their own competitive logic, converging 
sporadically. 
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 To commercialize an innovation, activities must start at idea generation and end 
in product introduction into the market. A detailed analysis of the literature reveals that 
the journey from one end to the other in this process is far from simple, with the 
inclusion of innovation protection, transforming the innovation to into product and 
other critical steps. It is of great importance to perform every activity in a precise 
manner to achieve success. However, there is no suggested uniform methodology in the 
literature that could define the process of successful commercialization. Out of every 
three thousand new innovative ideas, only one gets to become a successful product 
(Stevens & Burley, 1997). Looking at it from another perspective, it takes three 
thousand raw ideas to result in one successful product (Stevens & Burley, 1997; Dutta 
2011). 
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2.14 Commercialization of Technology 
 
Successful and innovative technology commercialization (TC) is important for 
survival in today’s competitive markets (Cooper, 2000). Mitchell and Singh (1996:170) 
view TC as ‘the process of acquiring ideas, augmenting them with complementary 
knowledge, developing and manufacturing saleable goods, and selling the goods in a 
market.’ 
Successful TC is multifaceted. It refers to a firm’s ability to: (1) develop and 
introduce a large number of product and process technologies (Zahra and Covin, 1993); 
(2) create radically new products (Zahra, 1996); (3) expedite the introduction of these 
new products to the market (Stevens, Burley, and Divine, 1999); and (4) create new 
knowledge (Leonard-Barton, 1995). These dimensions should be considered 
simultaneously in order to understand the factors that influence technology 
commercialization (Zahra and Nielsen, 2002). 
Commercialization of technology is often done by private firms (Rogers, 2003). 
However, the technology embodied in a new product has no value for the firm unless it 
provides significant new or improved customer benefits, or reduces product costs 
(Abetti & Stuart, 1988). The commercialization of technology can happen in various 
ways and the form it takes depends on the competencies of an underlying organization. 
There are many alternatives that can be adopted to commercialize innovation such as 
licensing, R&D contracting, partnering, alliances, and joint ventures (Arora & 
Grambardella, 1990; Kollmer & Dowling, 2004). A firm can market a technological 
innovation by selling complete patents to external parties (Katz & Shapiro, 1985; 
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Dodgson, 2000). Another way to achieve technology commercialization is creating a 
joint venture (Zajak, 1991) or establishing a strategic partnership or alliances (Steele, 
1989; Grant, 2002). Joint ventures help a firm share the business risk and combine 
complimentary assets and resources between two or more firms. However, joint 
ventures are sometimes hard to manage due to potential conflicts of interest (Simula, 
2012). 
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2.15 Commercialization of Product 
Cooper and Kleinschmidt (1990) used the term commercialization to describe 
trial production and sales, production start-up, and market launch. The focus of this 
dissertation lies on the commercialization within the context of the product (Medical 
device) innovation process. The literature on product innovation typically considers 
product innovation process to comprise three phases: a front-end phase, a development 
phase and a commercialization phase (e.g., Buckler, 1997; Koen et al., 2001). This type 
of linear approach with separate activities is also considered by the new product 
development (NPD) literature, too (e.g., Cooper, 1996; Khurana & Rosenthal, 1997; 
Griffin, 1997; Schilling & Hill, 1998) (Simula 2012). 
The path of commercializing a new product can be complex and may involve 
heavy risk and unforeseen surprises (Norling 1998). It may require more investment 
and can be more risky than several other alternatives to commercialization in the sub 
sections above (Di Benedetto, 1999; Kotler & Keller, 2009). According to Mitchell and 
Singh (1996), a collaborative relationship is beneficial in the case of the 
commercialization of complex products.  Another factor that may differentiate 
technology and product commercialization is the capability of a single technology to 
provide base for different projects and several new products (Parker & Mainelli, 2001).  
For example a technological invention to detect breast cancer may be exploited 
further to detect a pancreatic cancer. The same technology may also be used for doing 
biopsies in different contexts. Thus, a single project is not sufficient enough to capture 
the full value of a single technology base. Cook (1997) says that “[it] may not be clear 
which new technology is the most appropriate to carry the product in future”. Thus, a 
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firm that chooses to commercialize new products has to keep a close eye on technology 
development because there can be radical changes in technology that make existing 
products obsolete (Simula 2012).  
The time period between an original invention and a commercialized product 
can be very long. Agarwal and Bayus (2002) studied 30 industrial and consumer 
innovations in the United State between the years 1849 and 1983. The average time 
between an invention and the actual commercialization of the product took 29 years.  
And then, another ten years before sales really took off. The process might have 
expedited in the recent years however for every medical product it still requires a great 
deal of time from invention to the actual sale of the product in the market. 
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2.16 Commercialization of innovation-Success and Failure- A Discussion 
The literature on innovation commercialization, especially from the journals 
with a focus on new product development, has paid significant attention to the process 
of developing an innovation. Successful product development requires achievement of 
three objectives: (a) maximizing fit with customer requirements, (b) minimizing time to 
entry, and (c) controlling development costs. Parallel development processes and 
coordination between marketing, manufacturing and R&D has not only minimized 
entry time and controlled development cost but also allows for a fair understanding of 
customer needs (Clark & 27 Wheelright., 1993; Cohen & Levinthal, 1990; Griffin & 
Hauser, 1992). This section covers both the success and failure sides of the innovation 
mainly product related. Success and failure are two sides of the same coin and they are 
often researched in dyadic setup (Simula 2012). 
 According to Montoya-Weiss and Calantone (1994), this approach most likely, 
dates back to the SAPPHO and New Product studies. According to Cooper (1979a), 
Project SAPPHO was the first study to actually differentiate between the success and 
failure of new products. Brockhoff and Chakrabarti (1988) state that: “It appears that 
while technical success is more readily obtained, commercial success is far from being 
guaranteed” (p. 173). These two dimensions − i.e. the technical and the commercial − 
are often used to measure success, but Abetti (2000) adds financial success as another 
dimension that should be investigated. A list of some of the core failure measures that 
are used by academicians and practitioners alike adapted from Griffin and Page is 
provided in Appendix G. 
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 According to Cooper (1975), the “failure label” is given to products whose 
initial sales fell below expectations While Cooper (1975) simply equates financial 
failure with product failure. Schneider (2004) refers to a study conducted in the 
consumer goods industry and says that products are failures if they are unable to obtain 
distribution in the first year of introduction to the market. 
 
Rehn and Lindahl (2011) describe failure in a qualitative case study: 
Thus, the failure was not made up of anything in particular, but by odds 
and ends, small mistakes and uncertainties, tipping the scale this way and 
that until the situation careened out of control.  
 
It is evident from this that there really is no specific formula for failure. In order 
to identify reasons for success comprehensive meta-analyses of product success have 
been done by several authors (Johne and Snelson (1988), Lilien and Yoon (1989), 
Griffin and Page (1993), Montoya-Weiss and Calantone (1994), Poolton and Barclay 
(1998), and Ernst (2002), among others). 
Goldenberg et al. (2001) explains that new products that include some familiar 
attributes are generally the most successful. He identified two main factors predicting 
success: (1) whether the product provides a solution to a customer’s problem, and (2) 
whether the product fits certain templates that describe changes in regularities during 
the evolution of the product. A more detailed description and examples of these 
templates are provided by Goldenberg, Mazursky, and Solomon (1999a, 1999b). On a 
different note Abetti and Stuart (1988) postulated that it is actually less risky to 
commercialize a completely new product if compared to a situation where a firm tries 
to replicate a competitor’s product.  
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According to Levy (1998), there are five factors that are of importance for high-
tech firms seeking success: (1) An innovation uncertainty factor, consisting of market, 
technology, and supply uncertainties for new products; (2) the human factor, i.e. the 
challenge of recruiting creative professionals capable of creating innovations; (3) an 
organization factor, i.e. 
the capability to create a culture and environment that nurtures innovations; (4) a 
management competence factor, i.e. the ability to bring in leadership and team spirit; 
and (5) know-how and know-why factors, which ensure that a firm is doing the right 
thing in the most efficient way (Levy, 1998). Kulvik (1977) found no single factor but a 
list of variables that would have been sufficient for success. 
Poolton and Barclay (1998), Cooper and Kleinschmidt (2000), Song and Parry 
(1987), Henard and Szymanski (2001), Cagan and Vogel (2002), Kulvik (1977), 
Connell et al. (2001) and several authors including the ones listed already in this section 
and the others not listed, have identified one common thing in the analysis of success of 
new innovation (product or technology)  and that common factor is that there is no 
single reason but a list of variables that acts as the deciding fate of an innovation. 
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Chapter3 
Research Methods 
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This chapter focusses on the research methodology and approach for this 
dissertation. It discusses the research approach used in this study to answer the two 
research questions. 
R1: What activities did technology innovators and researchers perform at  
NovaScan to initiate the process of commercialization?  
 
R2: What is the evidence that these approaches are successful? 
 
The answers to the above questions will help answer the main question-“What 
practices can be identified as the best practices engaged in the process of 
commercialization of a medical device innovation”. This chapter also discusses the 
reason to opt for a qualitative case research method over the quantitative methods The 
chapter also discusses the data sources and the data analysis used. 
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According to Peter and Olson (1983), there is semantic confusion regarding the 
variety of philosophical perspectives in science (Simula, 2012). Dewey (1933) outlines a 
general paradigm of enquiry that underpins the scientific approach, consisting of 
inductive discovery (induction) and deductive proof (deduction). According to Dewey, 
deduction begins with a universal view of a situation and works back to the 
particulars; in contrast, induction moves from fragmentary details to a connected 
view of a situation. Through the inductive approach, plans are made for data collection, 
after which the data is analyzed to see if any patterns emerge that suggests relationships 
between variables. From these observations it may be possible to construct 
generalizations, relationships and even theories. Gray D, in his book, ‘Doing Research in 
the Real world’ says, “Through induction, the researcher moves towards discovering a 
binding principle, taking care not to jump to hasty inferences or conclusions on the basis 
of the data” (2009). This study focusses on the highlighted elements of the research 
framework shown in Figure 3.1. 
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3.1 Epistemology 
  
Easterby-Smith et al. (2002) points out that having an epistemological perspective 
is important as it helps to clarify issues of research design. Crotty's (1998) ideas 
established the foundation for a research framework. He suggested that there exists a 
relationship between the theoretical stance adopted by the researcher, the methods used, 
and the researcher’s view of the epistemology (see Figure 3.1).  
Ontology is the study of being, that is, the nature of existence and embodies 
understanding of “what is?” whereas epistemology tries to understand what it means to 
know. Epistemology provides a philosophical background for deciding what kinds of 
knowledge are legitimate and adequate.  
 
 
Methods 
• Sampling 
• Questionnaire 
• Observation 
• Focus group 
• Document analysis 
• Content analysis 
Methodology 
• Experimental research 
• Survey research 
• Ethnography 
• Phenomenological 
research 
• Case Study 
• Grounded theory 
• Heuristic inquiry etc. 
Theoretical 
perspectives 
• Positivism 
• Interpretivism 
• Symbolic 
interactionism 
• Phenomenology 
• Ideographic 
• Nomothetic 
• Critical inquiry 
• Feminism 
• Postmodernism 
Epistemology 
• Objectivism 
• Constructivism 
• Subjectivism 
Figure 3.1 Examples within Crotty’s knowledge framework, from Crotty, 1998 
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Objectivism in epistemology, for example, holds that reality exists independently 
of consciousness – in other words, there is an objective reality ‘out there’. So, research is 
about discovering this objective truth. A theoretical perspective closely linked to 
objectivism is positivism. The positivist approach can be called nomothetical; the idea 
behind it is that research procedures are formal, structured, and standardized to create 
empirically observable and experimentally verifiable proofs (Pihlajisto, 1994). Positivism 
has been described as ‘one of the heroic failures of modern philosophy’ (Williams and 
May, 1996: 27). 
In contrast to objectivism, constructivism rejects this view of human knowledge 
that truth and meaning exist in some external world. Constructivism supports that truth 
and meaning are created by the subject’s interactions with the world. Meaning is 
constructed not discovered, so subjects construct their own meaning in different ways, 
even in relation to the same phenomenon.  
For subjectivism, meaning does not develop from the interaction between the 
subject and the outside world, but is forced on the object by the subject. Subjectivism is 
based on a becoming ontology. Using the epistemology of constructivism, this 
dissertation focused on studying NovaScan LLC.  
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3.2 Theoretical Perspective 
 
A theoretical perspective linked to constructivism is interpretivism. Yet, while 
interpretivism and objectivism hold different epistemological positions, both are still 
based upon a being ontology (Chia, 2002). The world is interpreted through the 
classification schemas of the mind (Williams and May, 1996). As mentioned above, 
interpretivism is closely linked to constructivism. Interpretivism asserts that natural 
reality (and the laws of science) and social realities are different and therefore require 
different kinds of methods. While the natural sciences are looking for consistencies in the 
data in order to deduce ‘laws’ (nomothetic), the social sciences often deal with the actions 
of the individual (ideographic). 
The “idiographic,” approach is applied in this dissertation. The dissertation 
describes commercialization of healthcare innovation as a social phenomenon rather than 
a natural science phenomenon (Welch, Piekkari, Piakoyiannaki, & Paavilainen-
Mantymaki, 2011). 
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3.3 Methodology 
Insights about innovation, commercialization and technology transfer are obtained 
through an empirical study of NovaScan LLC. The company was founded in the year 
2003 and is developing a technology to detect breast cancer using electrical properties of 
the human tissue. The technology will be used to detect cancerous tissue within the 
surgical cavity of a partial mastectomy. More details about this company will be 
discussed in chapter four and specifics to why this company was chosen as a case study 
will be discussed in this chapter in the following sections. 
Robert Stake classifies case study research into three types:  
1. Intrinsic case study (where the interest is to only understand the particulars of the 
case).  
2. Instrumental case study (where the interest is in understanding something more 
general than the case).  
3. Collective case study (where interest is in studying and comparing multiple cases 
in a single research study). 
One of the central pieces of this dissertation is to describe the case study in depth, 
gather data and seek answers to the research question by abductive reasoning whereby 
one seeks to explain relevant evidence by beginning with some commonly well known 
facts that are already accepted and then working towards an explanation.(Source: 
Business Dictionary) 
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 Phenomenological case study research methodology forms the core of the effort. 
Phenomenology holds that any attempt to understand social reality has to be grounded in 
people’s experiences of that social reality. It expands on more traditional approaches 
(Peter and Olson 2077).  
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3.4 Methods 
In this research work, several data collection techniques have been used such as 
personal observations, documentation, audio-visual recordings, document and text 
analysis and other related contents analysis. This methodology is ideally suited to study 
TT or commercialization of innovation processes for several reasons that are discussed in 
this chapter.  
This data-collection technique integrates personal conversations with participants 
and allows the researcher to capture the essence of each experience familiar to the 
participant (Thompson, Locander, Polio 1989). With this increased amount of 
information, we can create a better understanding of how the variables are related and 
further analyzed. Rather than aiming to generalize, the inquiry develops an ideographic 
body of knowledge that describes NovaScan LLC as an individual case and the case 
study results are presented in the form of a theory.  
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3.5 Research Approach 
 
 
Figure 3.2 Research Approach adapted from Saunders et. al., 2007 
 
There are several questions that can be raised around commercialization of 
innovations in healthcare: can commercialization be identified, described, and measured? 
(Simula 2012). 
The purpose of this study is to provide an answer to the research question by 
combining the extant literature with the empirical data and by creating variables that 
characterize commercialization. The body of knowledge derived from the extant 
literature covers the fields of technology, innovations, technology transfer, innovation 
management, commercialization and strategy related material (Simula 2012) and the 
empirical data obtained from the case studied here. Table 3.1 summarizes the qualitative 
research method for case study analysis.  
Data Collection 
(Observations, document, archives and so on) 
Longitudinal 
(Time Frame) 
Case Study (Research Methodology) 
Inductive  
(Research Approach) 
Interpretivism 
(Theoretical Perspective) 
Constructivism 
(Epistemology) 
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The constructivism and Instructivism paradigm that acknowledges that there are 
no absolute realities (Figure 3.2) is used here. The research approach is the inductive 
research approach and I chose NovaScan LLC is a case study over a longitudinal time 
frame using various data collection methods. The data collection methods are explained 
in detail in section 3.8. 
Qualitative Research Approach 
Dimensions Case Study 
Research purpose To describe the case study in depth and answer the research questions 
Disciplinary origin Multidisciplinary including management , medicine etc. 
Primary Data 
collection method 
Personal observations, document and content analysis, published interviews, 
Audio recordings 
Data analysis 
approach 
Listing significant statements and identifying meanings, holistic description 
and search of themes shedding light on the case 
Report focus Rich description of essential context , discussion of themes issues and 
implications 
 
Table 3.1 Qualitative Research Approach 
Source: Adapted from http://www.southalabama.edu/coe/bset/johnson/lectures/lec12.htm 
 
The purpose of phenomenological research as described in various literatures is to 
gain an accurate understanding of another’s experience, to capture in-depth reflections by 
participants regarding their experience of an identified phenomenon (Creswell, 2007).  
A case study explores a phenomenon through one or more cases within a 
circumscribed setting or context. Therefore, this dissertation utilized a phenomenological 
approach to explore the practices of innovation and commercialization of breast cancer 
detection device at NovaScan LLC. While commercialization of all innovations may 
seem to be the natural and obvious route, this phenomenon is very case specific. The 
objective of this dissertation is to provide observations and discussion about how it is 
practiced and whether it will be possible to create a theory based on these observations. 
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3.6 Qualitative Case Study of NovaScan LLC as a Research Method 
This dissertation as discussed in the previous sections uses qualitative research 
methods for investigation. The qualitative case-study method has a long and respected 
history in the mainstream management literature. The method is also gaining acceptance, 
along with other qualitative methods, within the small business and entrepreneurial 
research community. (Perren  2004). 
As Denzin and Lincoln explain:  
Where only statistics, experimental designs, and survey research once 
stood, researchers have opened up to ethnography, unstructured 
interviewing, textual analysis, and historical studies. Where “We’re 
doing science” was once the watch-word, scholars are now 
experimenting with the boundaries of interpretation, linking research 
to social change, delving into characteristics of race, ethnicity, gender, 
age and culture to understand more fully the relationship of the 
researcher to the research. In various disciplines in various guises, this 
implicit critique of the traditional worldview of science and 
quantitative methods is taking place. All of these trends have fallen 
under the rubric of “qualitative research.” (Denzin 1994)  
 
Most qualitative researchers would agree with Snider’s (2010) observation that 
numbers impress, but unfortunately, also conceal far more than they reveal. They would 
also agree with Davis’s (2007) observation that “good qualitative research has equaled, if 
not exceeded, quantitative research in status, relevance, and methodological rigor”. 
Qualitative studies can be traced back to the earlier part of the 20thCentury (Lindlof 
1995). Deemed as “soft scientists,” qualitative researchers fought to have their 
methodology recognized and appreciated by the social scientific world (Denzin 1994; 
Lindlof 1995; Silverman 2000). 
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Misunderstanding Restatement 
General knowledge is more valuable than context specific 
knowledge.                    
 
Universals can't be found in the study of human affairs. 
Context- 
dependent knowledge is more valuable. 
One can't generalize from a single case so a single case 
doesn’t add to the scientific development. 
Formal generalization is overvalued as source of 
scientific development; the force of single example is 
underestimated. 
The case study is most useful in the first phase of research 
process; used for generating hypothesis 
The case study is useful for both generating and testing 
of hypothesis but is not limited to these activities. 
The case study confirms the researchers preconceived 
notions 
There is no greater bias in case study towards 
confirming preconceived notions that in other form of 
research 
It is difficult to summarize case studies into general 
propositions and theories 
Difficulty may be due to properties of realtiy, not the 
research method 
 
Table 3.2 Five Misunderstandings about case study research, Adapted from Flyvbjerg (2006) 
 
In an interesting discussion of the value of case study research, Flyvbjerg (2006) 
sets up five "misunderstandings" about case study research, which he then dismantles, 
substituting a more accurate statement about the issue underlying each misunderstanding. 
These misunderstandings and their restatements are displayed in Table 3.2. 
Yin (2009, p. 19), a recognized leader in case study methods, emphasized that 
case studies may also be useful for explaining presumed causal links between variables. 
However, the orientation of qualitative researchers contrasts sharply with that of 
quantitative researchers on many dimensions. The debate between comparable, case-
oriented (i.e. qualitative) research and large-N, variable oriented (i.e. quantitative) 
research streams has been ongoing and rather extensive (Ragin, 1997). Both methods of 
research, according to Ragin (1997), aim to “construct representations of social 
phenomena from evidence” (p. 40). However, the goal of case research is to increase the 
depth of existing knowledge and the contextual richness of the findings rather than focus 
on the representativeness of large-N research (Bonoma, 1985). It generates questions that 
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are answered with an emergent methodology, and works with rich sources of data that 
requires creativity for its analysis. 
Qualitative research, in all of its complex designs and methods of data analysis, is 
guided by the philosophical assumptions of qualitative inquiry: To understand a complex 
phenomenon, you must consider the multiple “realities” experienced by the participants 
themselves—the “insider” perspectives. 
As a participant observer at NovaScan, this researcher played the role of an 
insider since late 2008. More details about the association and involvement with 
NovaScan LLC are described in the next section and in chapter five. The researcher’s 
role as an insider within the company helped in identifying several aspects that as an 
outsider it would be difficult to have access to.  
Theoretical ideas are important in case study design and are usually developed 
prior to data collection, since they guide the type of data collected. As Orton (1997) 
states, “in a study where neither the theory nor the data is fixed, research improvisation 
works better than research design”.  
This kind of approach for this dissertation is appropriate because the objective of 
this dissertation is to identify an emergent theory (Glaser & Strauss, 1967; Eisenhardt, 
1989) or phenomenon about commercialization within the context of health care 
innovations focused on medical devices.  
The essence of the case-study method is a research strategy focusing on 
understanding the dynamics (Eisenhardt, 1989) and investigating contemporary 
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phenomena in real-life contexts (Yin, 1994). The case study method focusses not so 
much on statistical generalization as it does on analytical generalization (Yin 1994).  
This dissertation was undertaken in health sciences and has been developed with 
management studies perspectives. Thus it can be linked with the broader category of 
Social Sciences. The research tradition in these fields has often emphasized the role of 
drawing conclusions based on deductive reasoning (Bonoma, 1985). The traditional 
deductive approaches are concerned with developing propositions from current theories 
and making them testable in the real world, whereas inductive approaches rely more upon 
a phenomenological or grounded-theory type of an approach where theory is 
systematically generated from the data (Dubois & Gadde, 2002). The inductive approach 
is a useful path for scientific learning. 
The case-study method is suitable for topics in which existing theories seem 
inadequate or in which a fresh perspective is needed (Eisenhart 1989). Eisenhardt (1989) 
and Yin (1994) are in the qualitative world, often referred for justifying case studies as a 
research method .Their case analysis is focused primarily on theory of positivism. 
However, there are several other theories available. For example, Stake (1994) advocates 
a more constructive approach, Burawoy (1998) a more reflexive approach, and Dyer and 
Wilkins (1991) a more interpretative approach.  
The focus area of this dissertation is to identify and uncover the issues and factors 
underlying the phenomenon of commercialization of medical device innovations in health 
care. It was found in the previous chapter of literature review and analysis that there 
exists inadequate information about evidence-based best practices of commercialization. 
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Such an aim would require using a qualitative research methodology and possibly an 
interpretive as opposed to a positivist theoretical perspective (Levy 2006). 
A number of other disciplines incorporate interpretivist methodologies where the 
primary assumptions are that:  
 
“…access to reality (given or socially constructed) is only through social 
constructions such as language, consciousness and shared meanings. Such 
interpretive research does not predefine dependent and independent 
variables, but focuses on the full capacity of human sense making as the 
situation emerges” (Myers, 1997). (Levy 2006) 
 
A main topic of this dissertation, “identifying practices of innovations and 
commercialization at NovaScan LLC” is a topic that is best served by the case-study 
method. Based on the literature review conducted in this dissertation, the researcher does 
not hesitate to claim that, as of today, commercialization within the context of a new 
medical or non-medical device is an unclear and an emergent concept (Simula 2012). 
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3.7 Role as a Researcher  
 
The qualitative researcher’s perspective is perhaps a paradoxical one: it is to be 
acutely tuned-in to the experiences and meaning systems of others—to indwell—
and at the same time to be aware of how one’s own biases and preconceptions 
may be influencing what one is trying to understand. (Maykut & Morehouse, 
1994, p. 123) 
 
 
In qualitative research, the researcher is an instrument as Patton says, “he interacts 
and collaborates with the participants, and he gathers data by himself”. However, in 
quantitative research, the researcher uses instruments to collect data and does not interact 
with his participants. 
Qualitative research, in all of its complex designs and methods of data analysis, is 
guided by the philosophical assumptions of qualitative inquiry: To understand a complex 
phenomenon, you must consider the multiple “realities” experienced by the participants 
themselves—the “insider perspectives”.  
The data collection technique was based on the strategy discussed above. This is 
relevant more as qualitative because it allows researchers to work closely with 
participants within an organization and collect information pertaining to their personal 
thoughts and experiences (Yin, 2003; Bonoma, 1985). 
In qualitative studies the role of a researcher is very different from that in 
quantitative research. That is, in a perfect quantitative study scenario, participants act 
independently of the researcher as if he or she were not there. In correlational studies, the 
data are collected without regard to the participants or the person collecting the data 
(Simon 2011). 
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As a qualitative researcher with full participation in all commercialization 
activities and programs at NovaScan LLC, even before formal organizational 
participation, as an outsider, some observations were noted that also contributed towards 
data collection. In qualitative case study analysis, sometimes a researcher starts as an 
outsider and then becomes a member of the group. Or the reverse can occur –the 
researcher starts as a member of a group then becomes a more objective observer (Punch, 
1998).  
The informal documentation of observations at NovaScan started as early as 2008. 
The researcher was not an employee of the organization and was not involved formally in 
any of the company related activities then. Several activities were observed and noted 
that contributed to the theoretical basis for this dissertation. These ideas were not 
concrete enough to be identified as proper research questions. However, they helped in 
formulating a guide to the design of NovaScan study. This approach of generating 
theoretical ideas is important in case study design and are usually developed prior to data 
collection, since they guide the type of data collected. 
Adler and Adler (1987) identified three “membership role” of qualitative 
researchers engaged in observational methods:  
(a) Peripheral member researchers, who do not participate in the core activities of 
group members;  
(b) Active member researchers, who become involved with the central activities 
of the group without fully committing themselves to the members’ values and 
goals; and  
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(c) Complete member researchers, who are already members of the group or who 
become fully affiliated during the course of the research.  
 
Initially, the observations documented in 2008 at NovaScan were the first 
category of observational method. Later as a curriculum practicum trainee, data was 
collected as a complete member researcher. The population for this study consisted of 
NovaScan employees of which the researcher was one for over five years, starting first as 
an outsider and then as an insider.  
Insider research refers to when researchers conduct research with populations of 
which they are also members (Kanuha, 2000) so that the researcher shares an identity, 
language, and experiential base with the study participants (Asselin, 2003). The complete 
membership role gives researchers a certain amount of legitimacy and/or stigma (Adler & 
Adler, 1987).The stigma refers to the view of outsiders, who might see this role as 
creating a heightened level of researcher subjectivity that might be detrimental to data 
analysis and even collection(Dweyer C, Buckle J. 2009). 
A research strategy should involve multiple investigators and visiting the 
company in teams to increase the confidence of the findings (Pettigrew, 1990; Eisenhardt, 
1989). However, due to the nature of the PhD dissertation as an individual assignment, 
this project was investigated only by the researcher.  
However, being an insider is not without its potential problems (Adler, 1990). In 
Adler and Adler’s (1987) discussion of complete member researchers, they suggest that 
in this “ultimate existential dual role”, researchers might struggle with role conflict if 
they find themselves caught between “loyalty tugs” and “behavioral claims” (Brannick & 
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Coghlan, 2007, p. 70). Asselin (2003) has pointed out that the dual role can also result in 
role confusion when the researcher responds to the participants or analyses the data from 
a perspective other than that of researcher. She observed that role confusion can occur in 
any research study but noted that there is a higher risk when the researcher is familiar 
with the research setting or participants through a role other than that of researcher.  
Even though these issues have been identified by several scholars, the data 
collection for this study was mostly unbiased as it was mostly based on observational 
facts of organizational developments, meeting notes and other company literature facts. It 
was not dependent on data obtained through personal interviews or structured focus 
groups. More details on data sources are discussed in the next setion. 
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3.8 Data Sources and Collection 
 
Levy (1988) used a single-case design for the study at the University of Arizona. 
Yin (1994) said that single cases may be used to confirm or challenge a theory, or to 
represent a unique or extreme case. Yin (1994) listed six sources of evidence for data 
collection in the case study protocol: documentation, archival records, interviews, direct 
observation, participant observation, and physical artifacts and mentioned that all need 
not be used in every case study (Yin, 1994). In this study formal interviews are not 
relevant, since the intention is to identify the phenomenon of commercialization as a 
process and not as a view point.  
No single source of data collection has a complete advantage over the others; 
rather, they might be complementary and could be used in tandem. Thus a case study 
should use as many sources as are relevant to the study (Tellis, W. 1997). Table 3.3 
summarizes some strengths and weaknesses of each type of data collection method. 
Following the guidelines of Yin (1994) for using case study as a research method 
and data collection procedures and Eisenhard (1989) for theory building from case 
studies, NovaScan LLC was chosen as a case study. 
The case study approach typically combines data collection methods such as 
archives, interviews, questionnaires, and observations (Yin 1989). Other data collection 
devices are oral histories, and specimen records (behavior recorded through observation). 
However, the choice of data collection methods is also subject to constraints in time, 
financial resources, and access. Qualitative research data records are typically quite 
massive. 
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Source of Evidence Strengths Weaknesses 
Documentation • Stable - repeated review  
• Unobtrusive - exist prior to case  
study  
• Exact - names etc.  
• Broad coverage - extended time 
• Retrievability - difficult  
• Reporting bias – may reflect author bias  
• access - may be blocked  
Archival Records • Same as above  
• precise and quantitative  
• Same as above  
• privacy might inhibit access  
Interviews • targeted - focuses on case study 
topic  
• insightful - provides perceived 
causal inferences  
• bias due to poor questions  
• response bias  
• incomplete recollection  
• reflexivity - interviewee expresses what 
interviewer wants to hear  
Participant 
Observation 
• Same as above  
• insightful into interpersonal 
behavior  
• Same as above  
• bias due to investigator's actions  
Physical Artifacts • insightful into cultural features  
• insightful into technical operations  
• selectivity  
• availability  
Table 3.3 Strenghts and weaknesses of data collection method 
 (Adapted from Application of a Case Study Methodology by Winston Tellis, 1997, (Yin, 1994, p. 80)) 
 
 
Also, the qualitative researcher is advised to keep fairly detailed records of his or 
her thoughts, feelings, and behaviors while data are collected. It is important to determine 
whether or not the researcher is himself or herself a source of bias. 
 For NovaScan case study, a combination of archives, observation and informal 
discussions with main emphasis on the first two were main sources of data. Conducting a 
survey was inappropriate due to the lack of established concepts and indicators. 
Observation here refers to participant observation as the researcher was recording the 
observations systematically as an insider. The general questions that were covered during 
informal discussions are shown in Appendix D. 
Participant observation is the process enabling researchers to learn about the 
activities of the people under study in the natural setting through observing and 
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participating in those activities. Observations enable the researcher to describe the 
existing situations under study (Erlandson, Harris, Skipper, & Allen 1993). 
As suggested by Bernard (1994), as a participant observer, a rapport was 
established as an insider with the company professionals and it blended in such a way 
that the research did not affect the natural setting of people and organizational processes. 
Then, to be immersed in the data collected by different ways and be able to analyze, the 
researcher got disassociated from the organizational settings at NovaScan LLC in late 
December of 2012.  
Participant observation is characterized by actions such as having an open, 
nonjudgmental attitude, being interested in learning more about others, being aware of 
the propensity for feeling culture shock and for making mistakes, the majority of which 
can be overcome, being a careful observer and a good listener, and being open to the 
unexpected in what is learned (DeWALT & DeWALT, 1998). This was used as a 
strategy for making all the observations and taking field notes by the researcher.  
Participant observations contributed the most for data sources and the reason why 
they were chosen as a primary source of data collection are many fold. Schmuck (1997) 
describes that this method provides researchers with ways to check for nonverbal 
expression of feelings, determine who interacts with whom, grasp how participants 
communicate with each other, and determine the amount of time spent on various 
activities.  
. DeMUNCK and SOBO (1998) provide several advantages of using participant 
observation over other methods of data collection. These include that it affords access to 
the "backstage culture”; it allows for richly detailed description, which they interpret to 
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mean that one's goal of describing "behaviors, intentions, situations, and events as 
understood by one's informants" is highlighted ; and it provides opportunities for viewing 
or participating in unscheduled events.  
DeWALT and DeWALT (2002) believe that "the goal for design of research using 
participant observation as a method is to develop a holistic understanding of the 
phenomena under study that is as objective and accurate as possible given the limitations 
of the method”. 
While, DeWalt and DeWalt (2002) add that it improves the quality of data 
collection and interpretation and facilitates the development of new research questions or 
hypotheses, they also emphasize on the limitation that male and female researchers have 
access to different information, as they have access to different people, settings, and 
bodies of knowledge. However, this was not a concern in this case study (research topic 
being a gender neutral).   
DeWalt, DeWalt, and WAYLAND (1998) pointed another potential limitation of 
researcher bias. They note that, unless ethnographers use other methods than just 
participant observation, there is likelihood that they will fail to report the negative aspects 
of the cultural members. The method of triangulation was used in this study by involving 
document analysis and informal discussions along with observations to avoid the problem 
of observation bias. 
A primary consideration in any research study is to conduct the research in an 
ethical manner, letting the community know that one's purpose for observing is to 
document their activities. DeWALT, DeWALT, and WAYLAND (1998) advise the 
researcher to take some of the field notes publicly to reinforce that what the researcher is 
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doing is collecting data for research purposes. The association of the researcher with the 
case study was based entirely on the proposition of data collection for this doctoral 
dissertation as curriculum practicum training. This made clear the researcher’s intentions 
from the very beginning of taking field notes and audio recordings. The group members 
were regularly reminded of the audio recordings.  
The data collection for this study was more focused on the processes rather than 
personal opinions. The researcher promised to preserve the anonymity of the NovaScan 
LLC participants throughout the final write-up and in field notes to prevent their 
identification. The field notes taken as a participant observer have been the primary 
means of capturing the data. These notes include records of what is observed, including 
informal conversations with people at NovaScan LLC, records of activities and 
ceremonies and journal notes that were kept on a daily basis. 
There are several literature sources that describe the participant observation 
method and ways to conduct it. Werner and Schoepfle (1987, as cited in Angrosino & 
dePerez, 2000) focus on the process of conducting observations and describe three types 
of processes:  
1) The first is descriptive observation, in which one observes anything 
and everything, assuming that he/she knows nothing; the 
disadvantage of this type is that it can lead to the collection of 
minutiae that may or may not be relevant to the study.  
2) The second type, focused observation, emphasizes observation 
supported by interviews, in which the participants' insights guide the 
researcher's decisions about what to observe.  
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3) The third type of observation, considered by Angrosino and DePerez 
to be the most systematic, is selective observation, in which the 
researcher focuses on different types of activities to help delineate 
the differences in those activities (Angrosino & dePerez, 2000, 
p.677).  
Observation techniques for this study were influenced by the second and the third 
ways described above where focus was on commercialization activities of the case. The 
informal discussions and interviews guided the observation task and field notes. To keep 
the observations systematic and organized, a structured format for taking field notes and 
narrative reporting was developed for data analysis.  
Other researchers have taken a different approach to explaining how to conduct 
observations. For example, MERRIAM (1988) developed an observation guide in which 
she compiled various elements to be recorded in field notes. The first of these elements 
includes observing the surroundings of the setting and providing a written description of 
the context. Next, she describes the participants in detail and then she records the 
activities and interactions that occur in the setting. She also looks at the frequency and 
duration of those activities/interactions and other subtle factors, such as informal, 
unplanned activities, symbolic meanings, nonverbal communication, physical clues, and 
what should happen that has not happened. However, considering the research questions 
of this study, the Werner and Schoepfle (1987) model was chosen. 
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3.9 Data Analysis 
Case study is an ideal methodology when a holistic, in-depth investigation is 
needed (Feagin, Orum, & Sjoberg, 1991). Qualitative data analysis is mostly inductive—
the researcher identifies important categories in the data, as well as patterns and 
relationships, through a process of discovery. In Qualitative analysis there is often no 
predefined measures or hypotheses (Crotty 1998).  
For this dissertation, before the data analysis, all observations, documents, journal 
entries field notes and indirect interviews were documented and then transcribed. This 
transliterating allowed to become acquainted with the data (Reissman, 1993). For the 
purpose of data analysis the data is not coded sentence by sentence, rather it is focused on 
theme identification based on the underlying meaning. The analysis for this study also 
involves continuous back and forth linking of theory and data. This kept the focus on 
relevant literature (review method of literature has been discussed in the previous section) 
and then compare gaps in literature and also interact between the data and literature. 
Langley (1999) recommended this iterating process between theory and data during the 
analysis of data. 
For the thematic analysis, step by step guidelines have been followed as suggested 
by Braun and Clarke (2006). They recommend the word guidelines to highlight the 
flexibility of this qualitative analytic method.  
These guidelines are: 
(1) Familiarizing yourself with your data,  
(2) Generating initial codes,  
(3) The researcher read throughout each transcript to immerse in the data,  
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(4) Reviewing and defining themes, 
(5) Producing the report.  
In addition to the above, the triangulation method advocated by Yin (1994) and 
Denzin (1978) is also used. They emphasized on combining different sources of evidence 
and shifting between analysis and interpretation. For this study, several data sources such 
as internal reports, presentations, brochures, news, industry reports, annual reports, 
company web pages, informal discussion descriptions, notes have been used along with 
observations as the main data source (Simula 2012). 
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3.10 Validation Strategies 
As the area of qualitative research increases, social and behavioral scientists 
critique on the validity of studies that use such methodology. Thus, qualitative 
researchers utilize various validation strategies to make their studies credible and 
rigorous (Creswell & Miller, 2000). Credibility for this study was achieved using the 
validation strategies of triangulation, researcher reflexivity and rich observation and 
description. Bulmer states ‘qualitative researchers try to achieve validity not through 
manipulation of variables but rather through their orientation and the study of the 
empirical world’ (Bulmer, 1979).   
The observation data will be triangulated with the various other forms of data that 
were collected in this study (i.e., interviews, documents, reflective journal entries and 
field notes). As a basic foundation to achieve this, the researcher ensured that: (a) the 
case study research question is clearly written and (b) case study design is appropriate for 
the research question; (c) purposeful sampling strategies appropriate for case study have 
been applied; (d) data are collected and managed systematically; and (e) the data are 
analyzed correctly (Russell, Gregory, Ploeg, DiCenso, & Guyatt, 2005).  
Stake’s (1995) “critique checklist”, is used in this study to assess the quality of 
the report. This criteria checklist includes the following: 
• Is the report easy to read? 
• Does it fit together, each sentence contributing to the whole? 
• Does the report have a conceptual structure (for example, themes or 
issues?) 
• Are its issues developed in a serious and scholarly way? 
• Is the case adequately defined? 
• Is there a sense of story to the presentation? 
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• Are headings, figures, artifacts, appendixes, and indexes used 
effectively? 
• Has the writer made sound assertions, neither over-nor under- 
interpreting? 
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Chapter4 
Research Findings-Case study of NovaScan LLC 
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This chapter illustrates the case study for this dissertation. Researched here are 
backgrounds of the company chosen (NovaScan LLC), how its technological innovation 
of the Electrical Property Enhanced Tomography (EPET) took the form of two different 
medical devices and how they went from early innovation stage to the more formal 
commercialization stage. Following this description, this chapter includes a within case 
analysis of the case study. There are two case products discussed in this chapter. Pictures 
of both the case products are available in Appendix E. 
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4.1 Company Background 
 
NovaScan LLC was founded in 2003 to commercialize breast cancer detection 
technology. Though initially it was formed as a limited liability company for the purpose 
of conducting research on the electrical properties of tissue, and then to develop a 
commercial product which uses this technology. The founders, Dr. William Gregory, Dr. 
Christopher Gregory and Larry Wells, developed the technology at UW Milwaukee in 
collaboration with the Aurora Health Care in Milwaukee, WI. NovaScan is the exclusive 
licensee for patents related to this technology from WiSys, a division of WARF 
(Wisconsin Alumni Research Foundation). NovaScan’s mission is to develop and 
commercialize products using electrical properties to evaluate the health of human breast 
tissue.  
The company is in the early prototype stage of the development of a commercial 
product which is based upon its prior research. Since 2003, the company’s research and 
business operations have been funded by individual investors, awards from Wisconsin 
Governor’s business plan contest, institutional investor like Aurora Healthcare, 
Department of Commerce loans(Loan 1:TVF FY06_12397; Loan 2:TVF FY10_20259), and 
federal National Science Foundation (NSF) grants for both phase I and phase II (Grant 
number-1058413). 
The company is currently funded solely with grant funds and investors’ money. It 
has no commercial products on the market and no income from the sales of products, 
services, or licenses. Current revenue from grants comes from the federal NSF grants. 
The company received National Science Foundation Small Business Incentive Research 
(SBIR) Phase I, Phase Ia, Phase II and a Phase IIb grants for this research for a total of 
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$2.3 million, including external matching funds. NSF officials during a review 
presentation made by NovaScan LLC have recommended to National Institute of Health 
(NIH) for additional funding. This will provide a NIH match of up to $3 million to fund a 
FDA Pivotal Trial for approval to market in the USA. 
Figure 4.1 describes the lineage of the company. It shows various milestones it 
has achieved and the awards and grants it received along its commercialization path since 
its inception to 2011. Post 2011, the company has expedited its commercialization 
activities with some more strategic partnerships, initiating a pilot study of the device and 
searching for funding options from individual and institutional investors apart from 
federal grants.  
While federal grants will fund the development of a functional prototype, 
individual and institutional investors and possible NIH grants will fund the FDA trials, 
marketing, and manufacturing start-up. It is expected that FDA trials will take place in 
Year 2016-17, and that a commercial product will be introduced in 2018. 
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Figure 4.1 Company Background,  
Source:  NSF SBIR Ph II 2012 poster presentation, NovaScan LLC 
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4.2 Organizational Structure 
 
 
 
 
The company operates on a traditional corporate structure used by small firms. 
The stockholders elect the board of directors, responsible for the overall operations of the 
company. The board of directors appoints the officers of the company who are 
responsible for the day-to-day operations. William D Gregory, (PhD, Physics, 
Massachusetts Institute of Technology) is the founder of the company and is currently the 
Chief Science Officer and Chairman of the board of directors.  Wisconsin based Aurora 
Healthcare System is an investor and collaborator with the company.  
Board of Directors 
Chief Science Officer 
Lead Researcher 
Legal partner 
Sr. Elect. Engineer 
Sr. Software Engineer 
Accounting & Payroll 
Product Development 
Partners 
Medical Partner 
Aurora Health Care 
Figure 4.2 Organizational chart - NovaScan LLC 
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Aurora has provided NovaScan with tissue samples, access to personnel for 
evaluating the use of the technology in selected operational schemes, guidance for 
product development, use of their IRB procedure, use of laboratory space, and has 
invested funds into the company. Figure 4.2 shows the strategic role employment 
structure followed by NovaScan LLC. 
At present the role of CEO is played by the Chief Science officer, Dr. William D 
Gregory. However for effective operations, NovaScan is searching for a board member or 
CEO with successful experience in the medical device field in attracting angel and later-
stage investors, taking a prototype through to commercialization, and eventual sale of the 
company. The company also identified position of an advisor or board member who is 
well-connected to the angel investor and venture capital community to benefit flow of 
funds in the organization.  
The company made a strategic partnership with a Minneapolis based Product 
Development Company that not only assisted in developing the first prototype but also will be 
developing other improved versions of the prototype for FDA trials. This collaboration will help 
NovaScan achieve product development for FDA approvals and commercialization .This 
collaboration eliminated the need for an advisor who would assist in the process of obtaining 
FDA approval for the product. It will help NovaScan in commercialization of their devices get 
them fully International organization of Standardization (ISO) certified. They will also assist in 
obtaining CE mark in European Union. NovaScan has some more strategic alliances with the 
following: 
• Wisconsin Alumni Research Foundation (WARF) for patenting and 
patent portfolio management 
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• Michael Best Friedrich Law Firm for legal advice. Firm members attend 
companies Board of Director meetings, maintain the corporate records and 
review  the contracts and agreements 
• EWH Accounting- Payroll, tax management, monthly balance sheet 
preparation, year-end compilations 
The researcher was initially associated with the company during 2008 to 2010 on the 
University of Wisconsin, Milwaukee research grant and then later joined the company as a 
curriculum practicum trainee (CPT). The association with the company was solely for the purpose 
of working on this dissertation. The CPT contract ended at NovaScan in December of 2012. Since 
the disassociation the researcher has worked on documentation and organization of the collected 
data to present the findings in the form of this thesis. Under no circumstances the researcher held 
any authority to approve or disapprove of the NovaScan products. The association was entirely 
academia based.  
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4.3 The Case Product (1) 
 
 
4.31 Electrical Mammogram 
 
 
 
 
 
NovaScan’s imaging products will be based on Electrical Property Enhanced 
Tomography, or EPET.  According to NovaScan LLC, EPET is an in vivo technique that 
can be used to identify various structures within the interior of an object (e.g. the human 
body).  Because each tissue has unique electrical properties, EPET can be used to identify 
different tissues with the goal of distinguishing malignant from benign tumors. 
NovaScan’s system utilizes a geometrically shaped array of electric field sensors 
positioned around an object of interest (e.g. breast).   
Figure 4.3 Business Model for NovaScan Imaging Technology 
(Source: NovaScan Business Plan 2004) 
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These sensors measure the formation of charges on the boundary layers of 
different tissues over a range of electromagnetic frequencies.  The charges on the 
boundary layers relate directly to the dielectric and conductivity coefficients of the 
material being scanned, allowing the unique electrical properties of the tissue to be 
measured.  By performing these measurements, diseased (cancerous) areas can be 
distinguished from healthy tissues. 
 
4.32 Value Proposition 
 
By providing better screening and earlier detection, the product will increase the 
5-year survival rate of breast cancer patients and reduce the costs associated with the 
diagnosis and treatment of breast cancer. NovaScan’s direct consumer for this imaging 
product is the diagnostic imaging companies and/or distributor partners. They will be 
provided with a unique breast cancer detection tool that they can deploy as a marketplace 
differentiator and drive new sources of revenue. According to NovaScan LLC, this will 
ensure improved oncology screening and staging.  
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4.4 Case Product (2):  
 
4.41 FastPath TM Surgical Probe 
 
 
The FastPath TM surgical probe referred to here as case product (2) is the 
company’s first official product. The basis of technology remains the electrical properties 
of human tissue. The NovaScan Probe will provide breast cancer surgeons a tool to (a) 
determine if there are cancer cells remaining in the surgical cavity in real time during 
surgery, and (b) determine if excised tissue has clear margins during surgery in the 
surgical suite. 
Surgeons must now send excised tissue to the pathology lab for preparation and 
analysis, a procedure that can take 20-30 minutes, while the patient remains under 
anesthesia. Final analysis of excised tissue can often take 24-28 hours, which would 
require an additional surgery if the margins are not clear. The NovaScan Probe makes 
this analysis in seconds. 
 
Minimally Invasive
High Sensitivity of 0.94
and Specificity of 0.83
Low Power RF
Probe Works In 
Real Time
Ergonomics
Precise and accurate
Lower re-excision rates
No dyes/particles/radioactive materials
Requires no sample preparation
No side effects
Eliminates surgical delays
Detects malignancy in 
open wound during 
surgery in real time
Collects and analyses data
in seconds.
Works independently of mains voltage
No obtrusive wiring
Assured patient and operator safety
Hand held, ease of use
Results are obtained in real time
 
Figure 4.4 NovaScan’s FastPathTM surgical probe value proposition 
Source:  NSF SBIR Ph-II 2012 poster presentation, NovaScan LLC 
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4.42 Opportunity Identification-Market Drivers for the FastPathTM 
 
 
While NovaScan was trying to push their electrical mammogram technology to 
the potential consumer who were physicians and surgeons in a hospital setting, it was 
identified through several interviews an discussions that while the technology seems very 
promising, the need of the hour was a cancer detection device that could help identify 
cancer tissues real time and eliminate the repeat surgeries. NovaScan’s efforts in this 
direction are discussed in detail below and in section 4.5. 
The companies breast cancer collaborators guided NovaScan towards improvising 
their FastPathTM prior to the imaging device so that this hand held tool can be used in the 
surgical cavity to determine if all of the cancerous cells have been removed and that the 
surgical cavity is cancer free. NovaScan LLC claims this will help not only reduce the 
number of repeat surgeries but also minimize the follow up treatment of chemotherapy as 
well, the company claims. As a strategy NovaScan LLC rather than moving on the 
technology-push path, decided to move towards the technology-pull path which seemed 
profitable and a better business sense. 
Martin, Michael J.C. (1994) in his book Managing Innovation and 
Entrepreneurship in Technology based Firms defines technology pull and technology-
push the following way:  
 
A technology push implies that a new invention is pushed 
through R&D, production and sales functions onto the market 
without proper consideration of whether or not it satisfies a user 
need. In contrast, an innovation based upon market pull has been 
developed by the R&D function in response to an identified 
market need. (Martin, Michael J.C., 1994). 
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4.5 Opportunity Assessment and Commercialization Activities of NovaScan LLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prototype development, Pilot trial study design, 
Protocols and procedure specs. 
Electrical 
Mammogram 
Market 
Feasibility 
Technology 
and Reward 
Evaluation 
Concept 
Generation 
Identification of 
EPET Technology 
Business Case 
?
 
Reconsider 
positioning and 
strategy 
Scope 
Yes 
No 
Technology Push 
(a) Innovation and commercialization model for Electrical Mammogram 
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Generation 
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(b)Innovation and commercialization model for FastPathTM Surgical Probe 
 
Customer feedback 
 
Figure 4.5 NovaScan’s Commercialization models 
Customer feedback 
Customer Feedback 
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The company was formed as a limited liability company in 2003 for the purpose 
of conducting research on the electrical properties of tissue, and then to develop a 
commercial product which uses this technology. Initial research was focused specifically 
on developing an electrical mammogram which would be used in conjunction with 
existing x-ray mammography. This research proved successful in detecting cancerous 
cells to a far higher sensitivity and accuracy than traditional x-ray mammography. The 
research also showed that this technology was very applicable to differentiate various cell 
types, for example, distinguishing cancerous cells from benign cells. This indicated that 
the technology could be used to successfully avoid many of the biopsies that are 
undertaken just to be sure that cancerous cells are not present. As shown in figure 4.5(a) a 
business case was prepared based on the technological research success data .Based on 
the initial research success, the company officials decided to touch base with the 
consumers to assess the market for electrical mammogram.  
“While we had heard of the work of Steve Blank only recently (at the 
May 2012 NSF Phase II meeting), we inadvertently did exactly what he 
teaches, but with one twist: we spent several years acquiring data so we could 
present a full menu of possibilities to our audience. And, also as suggested by 
Blank, we found it advisable to PIVOT***  when our personal top choice of 
a ‘first marketable device’ was not supported by our customer interviews. 
The process to arrange visits, make a presentation, record feedback and sift 
through all of the comments took 18 months”, said Chief Science Officer, Dr. 
William Gregory of NovaScan LLC.  
 
 
 
*** Eric Ries coined this business model iteration loop – the Pivot. Pivoting” is when you change 
a fundamental part of the business model. (One of the Pivot’s positive consequences for the startup team is 
realizing that a lack of scalable revenue is not the fault of Sales or Marketing or Engineering departments – 
and the solution is not to fire executives – it’s recognizing that there’s a problem with the assumptions  in 
the initial business model.) Source: Why Startups are Agile and Opportunistic – Pivoting the 
Business Model, April 12, 2010 by Steve Blank (Fig. 4.8). 
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There were surprising results from the market assessment and contacts with 
hospitals. It was found that though the electrical mammogram technology was very 
promising, it still wasn’t the need of the hour. The hospital surgeons needed a device that 
could use this technology in breast cancer surgery. Apart from consumer feedback there 
were several other barriers identified like first and foremost the regulatory and then the 
list of well-established competitors. Many large well established firms (such as GE and 
Hologic with x-ray mammograms, MRI and US devices) dominated the breast screening 
market. And even though NovaScan device was superior in every way to the x-ray based 
technology, the medical community was not willing to shift from the well known 
technology.  It would be a fight to get to market suggesting that such a device would be 
more of a technology push. 
Choosing the better business sense, NovaScan shifted its focus to development 
and commercialization of the surgical probe that continues on this path today (Figure 
4.5(b)).  
 
Figure4.6 Usage scenarios of the FastPathTM surgical probe 
The company is in the early prototype stage of the development of a commercial 
product which is based upon its prior research. Figure 4.5(b) describes the process of 
FastPathTM 
Detect cancer on excised tissue 
Detect cancer within surgical 
cavity 
Scenario A 
Scenario B 
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commercialization of FastPathTM surgical probe. As per the diagram, it has accomplished 
most of phase 1, part of Phase 2 and is also working towards entering phase 3. The 
company strategically delayed the development of electrical mammogram and have plans 
to revisit the electrical mammogram market only after the FastPath™ probe has achieved 
most of the phase 4 (Figure 4.5(b)). 
Another strategic decision that NovaScan took was to split the usage scenarios to 
expedite the regulatory approval and product launch process(Figure 4.6) While the 
company has extensive research data available on excised tissue they decided to market 
the probe in Scenario A – where it will be used to examine the tissue removed during a 
Breast Conservation Therapy procedure (a partial mastectomy or lumpectomy) to 
determine that no cancer exists within a safe distance from the margin of the excised 
tissue (defined as 3-4 mm by most surgeons) and then later as Scenario B – where it will 
be used for testing the tissue within the surgical cavity to find any residual cancer(Figure 
4.6). 
During phase I a first version of the hand held probe, the alpha prototype, was 
developed while working on size of the device and electronics simultaneously. During 
later part of phase I another modified version of device was developed with a better 
sensitivity and technical programming and they called it the beta prototype. During phase 
2 Novascan made a strategic collaboration with a Minneapolis based product 
development company that could help Novascan progress towards development of Gama 
prototype while simultaneously working on various protocols and requirements for 
submitting it to FDA for Pilot trial approvals. This collaboration streamlined the 
development process. As per the diagram shown in Figure 4.5, the research team decided 
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to take improved prototype from latter part of phase 2 and begin testing in the surgery 
suite with both the first (A) and second (B) scenarios (Figure 4.6) discussed earlier. This 
step will help them develop a metric to characterize the medical value of the probe. The 
beta prototype was put to rigorous testing with a feedback mechanism to incorporate 
improvements suggested by the physician team members and the feedback will be 
incorporated into the final gamma prototype that will be submitted to FDA for Pre-
Market approval. 
As of July 2013, the company for its product FastPathTM surgical probe has an 
International Organization of Standardization (ISO) approval for use on humans. This 
probe that can be used in sterile or non-sterile conditions to scan tissue for breast cancer 
was tested during a continuation of the products current IRB studies and is ready for first 
marketing in Europe. At the end of the European Union introduction of the probe the 
company will begin the FDA Pivotal Trial process to obtain US marketing approval.  As 
a strategy, NovaScan plans to start the process of commercialization of the electrical 
mammogram device as a follow-on product to the surgical probe. 
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4.6 Product Market Launch 
 
 
 
Figure 4.7 FastPathTM surgical probe market launch steps 
 
At first the Pilot Study results will be used to apply for outside United States 
regulatory approval, notably in Europe for a CE mark.  Then the results will be shared 
with FDA while negotiating on a plan for the Pivotal Trial as a necessary part of the 
application for a Pre-Market Approval (PMA). The National Science Foundation grant 
has funded the development and testing of the initial prototype of the surgical device. 
However, for FDA trials, marketing, and manufacturing of the product, a funding of $3 
million in future revenue from individual and institutional investors will be sought. It is 
expected that FDA trials will take place in 2016-17, and that a commercial product will 
be introduced in 2018.  
The strategic alliance with the Devicix will help NovaScan achieve outside 
United States (OUS) regulatory approval and start with early OUS sales. This will help 
decrease the demand for high external investments for the  Pivotal Trial. Without the 
OUS sales the company has to look for heavy investments to start with the Pivotal trial in 
US. 
 
FastPathTM 
Obtain Regulatory 
Approval(CE and 
FDA) 
International sales 
through distributors 
License or sell 
product to Medical 
device firms for 
broader 
commercialization 
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4.7 Role of Competition in Product Launch 
The competitive landscape for NovaScan is not too complex as there aren’t many 
players in the market for detecting cancer tumor margins. The only direct competitor for 
NovaScan is Dune Medical systems. They are in their Pre-Market Approval stage and 
that makes them ahead of NovaScan. However, Novascan has a competitive edge in 
terms of cancer detection capability over the Dune device. As mentioned earlier the Dune 
device is slightly ahead in the approval and market launch than NovaScan and this lead of 
the Dune device will help generate the market for NovaScan surgical probe. The fact that 
FastPathTM surgical probe measures both in the wound, and on the excised lump, will be 
a strong factor in competition with Dune. Nonetheless, NovaScan cannot delay the 
commercialization process as it might lose on the market pull and demand. Table 4.1 
shows the comparison of features of NovaScan FastPathTM with Dune’s device that they 
call as Margin ProbeTM. 
Feature NovaScan’s FastPathTM Dune’s Margin ProbeTM 
Scan surgical cavity Yes No 
Scan shavings Yes No 
Saline or gels Yes No 
Touch only (no vacuum) Yes No 
Avoids spatial avg. errors Yes No 
Works in hetero samples Yes No 
Can sense deep and close Yes No 
Scan Lump or Partial Mastectomy Yes Yes 
Likely to get PMA  late 2012, early 2013 No Yes 
 
Table 4.1 Feature comparisons of NovaScan FastPathTM with Dune’s Margin ProbeTM. 
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4.8 Within Case analysis 
“Our first thoughts had been to use this EPET technology for an electrical 
mammogram. In fact, we built such a device and tested it in a small study 
(N=50) at the Aurora Health Care hospitals in Milwaukee.The results of 
this small study were exceptional- no errors in identifying cancer from 
benign breast disease.And even though our device was superior in every 
way to the x-ray based technology, the medical community seemed loath 
to change from an older, well known technology.  It would be a fight to 
get to market.”- Dr. William Gregory,CSO NovaScan LLC. 
 
Several researchers have suggested that it is difficult to change the behavior of 
clinicians (Greco and Eisenberg, 1993), current medical practices, and healthcare 
organizations (Shortell, Bennett, and Byck, 1998; Shortell et al., 2001). The NovaScan 
innovators and researchers spent several years acquiring data to give its consumers a 
detailed idea of functional possibilites however their personal top choice of a ‘first 
marketable device’, in this dissertation referred as case product(1), was not supported by 
the customer interviews.   
 
Figure 4.8 Source: Why Startups are Agile and Opportunistic – Pivoting the Business Model, 
April 12, 2010 by Steve Blank 
 
NovaScan founders arranged visits with physicians, made presentations, recorded 
feedback and sifted through all of the comments. It took 18 months to firmly realize that 
there was something wrong with the initial business model (Figure 4.3). Their contacts 
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with surgeons and oncologists resulted in the discovery that a device that would solve the 
‘residual cancer’ problem using same technology would be more meaningful. That led 
NovaScan reconfigure some part(s) of their model. Figure 4.9 is a graphical 
representation of NovaScan’s approach with a difference that they did not form the 
company after pivoting rather they pivoted within the same company with a different 
product approach. 
Case Product Electrical Mammogram FastPathTM Surgical Probe 
Technology EPET EPET 
Product Uniqueness Accurate detection of cancer 
tissues in imaging mode 
Detects cancer real time during 
surgery 
Safety 
Hand held device 
Physicians requirement 
Product Driver Technology Push Technology Pull 
Radicallity Technology Market 
Technology 
Target Market Hospitals, Clinics Breast surgery Centers 
Hospitals 
Customer base Not established Mostly established 
 
Table 4.2 Product feature comparisons 
New practices in patient care are traditionally scrutinized thoroughly in their early 
development phase so that potentially harmful innovations are not adopted (Faulkner and 
Kent, 2001).Looking at the product value proposition of the NovaScan hand held surgical 
probe technology, safety has been a great USP (Unique Selling Proposition). While there 
have been some technologies available for detecting residual cancer, none promises to be 
free from side effects NovaScan surgical probe is free from any side effects and it uses no 
injectable dyes or external radioactive or non-radioactive agents. This property attracted a 
lot of attention from the stakeholders. 
For most healthcare innovation the stakeholders are patients, provider’s 
parameters and purpose (Figure 2.1). The NovaScan hand held surgical device provides 
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the patients with precise, lower re-excision rates and helps surgeons detect malignancy in 
the open wound during surgery in real time. It also, provides time reduction and several 
solutions to the existing breast conservation surgical procedure. This technology assures 
both patient and operator safety. As mentioned by Steve Blank, the path to success is 
connectivity with consumers; NovaScan has been in touch with all its consumers from 
very early stages. 
Moreover, while there were numerous competing technologies being studied to 
solve this problem detecting residual breast cancer  during surgery, real time, there are 
only a handful that are being commercialized. In fact, as of today, only one company , 
Dune Device has survived and is near to obtaining a Pre-Market Approval (PMA). for a 
device that is inferior to the NovaScan device (see Table 4.1). 
Professor Joe Tidd of University of Sussex at London claims that the early 
innovation models define innovation as a linear sequence of functional activities. He says 
either new opportunities arising out of research give rise to applications and refinements 
which eventually found their way to the marketplace (‘technology push’), or else the 
market signaled needs for something new which then drew out new solutions to the 
problem (‘need pull’, where necessity becomes the mother of invention).NovaScan’s 
modified business model can very easily relate to this approach. 
Roy Rothwell, a key researcher in the field of innovation management suggested 
that the innovation process has evolved from simple linear models (characteristic of the 
1960s) to increasingly complex interactive models (Figure 2.2). His first generation 
model stresses on technology pull and technology push method whereas the fifth concept 
sees innovation as a more complex, multi-actor process, which requires high levels of 
109 
 
integration. NovaScan’s FastPathTM Surgical Probe business model is seen basically as a 
technology pull method however it’s more complex in nature. It involves more strategic 
collaborations, customer feedbacks, raising funds etc. The company has developed a 
large suite of software programs, electronic circuitry and electrode configurations that 
will be tried during the Pilot Study. This Pilot Study is a pre-Pivotal Trial study. The 
probe prototype will be tested in real settings  for several performance parameters. Based 
on the feedback, the probe will go through changes, replacements and alterations 
necessary to bring the device to market. 
To achieve this, apart from being a promising functional device, the company 
must have the regulatory approval to enter the market. “The FDA approval, whether the 
less onerous 510K or the full PMA, will be the most important hurdle we must achieve to 
enter the market”, says Dr. William Gregory. He said that this is intimately tied to the 
market projections and the strategy we use to commercialize the device.  The strategy is 
to attempt a much less expensive 510K if a predicate device is available (such as the 
Dune device or earlier bio-impedance devices from companies such as T-Scan). The 
company plans to seek sufficient capital to pull together manufacturing and sales using 
strategic partnerships wherever possible. 
Case Product Success factors 
FastPathTM Surgical Probe 
Technology Pull 
Performance Parameters 
Consumer’ requirements of such a device 
Investments in the promising technology 
Strategic Partnerships 
Competitors landscape 
Customer reviews 
Safety features of the device 
Strong research team 
Table 4.3 FastPathTM Surgical Probe success factors 
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As shown in Table 4.3, there are several factors that may contribute to the 
successful commercialization of the FastPathTM Surgical Probe. As discussed in the 
earlier sections of this chapter, this product was developed keeping in mind the demand 
from the breast surgeons. The interviews with the end users helped company focus on 
need analysis of the technology as well as the product. The confirmation from the end 
users regarding need in the current market gave stimulus for further research and 
development of the product. The extensive research revealed the performance parameters 
discussed earlier (Figure 4.3). The initial technological success helped raise some money 
from grants, awards and investments from friends and family. It also paved the way for 
strategic partnership and investment for Aurora Healthcare.  
A detailed review of the competitor landscape revealed that there wasn’t any 
direct threat to the NovaScan’s technology and the potential, based on its functional 
parameters and safety promises was very high (Table 4.1). Another important factor for 
NovaScan’s commercialization success would be its strong research team. The value of 
human resource can never be underestimated. 
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Chapter 5 
Propositions for Managing Innovations and 
Commercialization  
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This chapter includes propositions that are based on the research findings 
discussed in chapter four. The propositions are derived from the analysis of the case 
study, but they are also combined with insights derived from the literature. The chapter 
presents seven propositions and a framework of commercialization based on the literature 
review and research findings.  
While the propositions can be read as general managerial suggestions, they are 
not intended to represent any ideal, law like guidelines. These propositions represent the 
researcher’s best effort, based on the literature and case study, to summarize what has 
been learned during the research process. In other words, while the propositions are 
formulated in a relevant and practical form, they should be considered as mere 
recommendations and the basis for theory. As mentioned in previous sections as well, the 
aim of this study is not to create statements of generalizations of facts. 
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5.1 Commercialization Process 
 
 
Proposition (1) Identifying critical steps of commercialization early in the processes are 
important to the success of commercialization. 
 
Successful product design and development requires the ability to take a concept 
and translate the technology into useful, patentable, commercial products by formulating 
a sound road map. The desired outcome of every such practical healthcare product 
research is to identify a viable and less trodden path for introducing research based 
innovations from the laboratories to the clinics and the bed side.  
While commercialization-related tools such as a Business Plans, Gantt Chart 
were often in place at NovaScan LLC, neither maps nor descriptions of the 
commercialization process or other documentation concerning commercialization existed  
in the early part of their product development. However, a more strategic 
commercialization plan was put in place while applying for the National Science 
Foundation SBIR Grant. This helped company re-identify its focus areas and target. 
Critical steps to successful development and commercialization of a healthcare product 
are: invention, patenting, planning early prototyping, and developing and implementing 
the commercialization of profitable medical product innovations. There is a need to 
develop a comprehensive and practical overview of the steps and challenges early on in 
the research and developmental stage to successfully develop and commercialize a 
product. This finding is in line with the findings of Prebble et al. (2008) that there is little 
understanding of the actual decision making that goes on when designing a 
commercialization process. 
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While it is not possible to generalize, it seems quite likely that many research 
based small firms lack clear commercialization processes. However, the firm under study 
viewed the commercialization process as an important topic but did not put it into 
practice early on. This led to Proposition 1, Identifying critical steps of commercialization 
early in the processes for success of commercialization. 
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5.2 Test Market- Internal Field Trials 
 
 
Proposition (2) First field trials play an important role in commercialization, especially 
when commercializing a technology intensive product. 
 
According to Deming (1988), 
 
A consumer can seldom say today what new product or new service 
would be desirable and useful to him three years from now, or a 
decade from now. New product and new type of service are generated, 
not by asking the consumer, but by knowledge, imagination, and 
innovation, and risk, trial and error on the part of the producer, backed 
by enough capital to develop the product or service and to stay in 
business during the lean months of introduction. (Deming, 1988) 
 
 
 
While the above statement was targeted at the non-healthcare business, the idea 
can be applied to the healthcare industry as well. The above statement does indicate that 
customer may be ignorant of his own wants and needs and therefore the customer 
interaction during the new product development and commercialization processes may 
take a back seat. Despite the clear statement above, which devalues the consumer as a 
source of ideas, Deming (1994) seemingly contradicts himself later on when he claims, 
“An educated customer may have a firm idea about his needs, what he would wish to 
purchase. He may be able to specify his needs so that a supplier may understand them”. 
NovaScan’s first thoughts were to use the EPET technology for an electrical 
mammogram. To move further in the development they built the device with some intial 
funding and conducted tests in a small study (N=50) at the Aurora Health Care hospitals 
in  Milwaukee. The results of this small study were exceptional- no errors in identifying 
cancer from benign breast disease. And even though company claims that the  device was 
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superior in every way to the x-ray based technology, the medical community did not 
accept this technology over the well known technology of mammograms. 
However, the positive outcome of this interraction with the physicians and breast 
cancer surgeons (consumer) was the demand for the hand held surgical probe to detect 
cancer real time while operating in the surgical suite. The EPET technology could be 
easily applied to this hand held device as well and based on this need based analysis 
NovaScan shifted its focus from electrical mammogram to the development of the 
surgical probe. 
 This shift meant a more promising evidence based solution to an existing 
problem of detecting breast cancer in the surgical cavity real time and a big leap to 
successful commercialization. This led to formulation of my Proposition (2): First field 
trials play an important role in commercialization, especially when commercializing a 
technology intensive product. Various articles seem to promote the holistic role of 
consumer in the innovation process. And the insights derived from the case study 
approves of this approach of involving consumer early in the process. 
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5.3 Consumer Testimonials 
 
Proposition (3) Positive consumer references and testimonials recommending a 
particular product play an important role in the commercialization 
 
 
Deming (1994) claims that, 
 
An educated consumer may have a firm idea about his needs. What he 
would wish to purchase. He may be able to specify these needs so that a 
supplier may understand them (Deming, 1994). 
 
 
The case study on NovaScan demonstrates that the consumer, even though not the 
originator of technology, can contribute useful ideas to an innovation process. In other 
words, a consumer may very well know what he or she wants, without knowing exactly 
how to achieve or implement those desires. Like in NovaScan case study the surgeons 
and physicians carved out the need of the hand held surgical device. It shows that while 
consumer understanding is important, it is even more important to be able to pinpoint and 
solve the problems a consumer is having.  In cases where a consumer cannot express her 
or his needs and wants, it is much more difficult for a developer to come up with a 
product that meets those needs and desires.  
This led to defining Proposition (3): Positive consumer references and 
testimonials recommending a particular product play an important role in the 
commercialization. 
As the diffusion of innovation theory (Rogers 2003) indicates, there are only a limited 
number of innovators and early adopters. Therefore, a firm is better-off in finding those 
innovative consumers as early as possible. NovaScan identified the group of surgeons 
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and physicians that helped in developing a more desired product from the same EPET 
technology early on.  
In addition, external opinion leaders play a crucial role in convincing potential 
future consumer. It is important to use testimonials and reports from industry experts to 
pave the way for a new product. This can be seen as one of the most important 
commercialization-related tasks and helped NovaScan in raising funds for the company 
(both through federal grants and external investors). 
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5.4 Product Launch Within the Organization 
 
Proposition (4) Implementing an internal product launch can be an important 
prerequisite for a successful commercialization. 
 
 
The management of internal information flows and knowledge management in 
general are much easier tasks to organize in a small startup firm than in a large 
corporation with several divisions around the globe. Larger firms view internal training 
and preparations as very important. A small firm may not need specific internal launch 
practices because the information is easy to spread. However, at NovaScan, even though 
the FastPathTM was not officially launched as a prototype, the company has plans to 
introduce a test batch within the hospital it is affiliated with. The surgeons will be 
allowed to use it and provide feedback. This will help as a test market for the device and 
any flaws and discrepancies witnessed by the surgeons in the first hand use will be easy 
to fix before a full-fledged launch. 
Lambert and Slater (1999) provide an example from the airline industry in which 
Southwest Air’s modest expansion outperformed People Express’s aggressive product 
introduction strategy. This illustrates that speeding a product to market is not always the 
best option. Lempres (2003) argues that while firms may have fine-tuned their processes 
as effectively as a fast production line, they also may have become so rigid that they 
cannot adapt to market changes. The solution is to foster flexibility and to try to keep the 
process dynamic and information-based. It is better to postpone a launch if product is not 
ready (Lempres 2003).  
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5.5 Role of Strategic Alliances 
 
 
Proposition (5) Successful commercialization requires a strong and competent facilitator 
or strategic alliances  
 
 
 
Figure 5.1 Facilitator’s role in the process of innovation to commercialization 
(Source: Shabistan Sheerin, IATI BioMed Conf 2013(Israel)) 
 
Identifying a facilitator early on in the process helps research based organizations 
to have access to critical resources like it may help in licensing, linking to product 
development agencies, research design, review of various protocols, access to industry, 
opportunities for collaboration and networking. It also helps in getting regulatory 
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approvals. This process of identification of this central agency (may be operated by a 
single man or another company) can help save on time in the development process and 
streamline resource allocations.  
NovaScan LLC saw this position as quite important not only for ensuring the 
technical functioning of a product, but also from the commercialization point of view. To 
fulfill this role they made few strategic tie ups. One was with Aurora hospitals that helped 
them in identifying and keeping constant contact with their real consumers. This also 
helped them in running the device through various testing phases at their hospital facility 
in Milwaukee.  
Second important strategic tie up of NovaScan LLC was with Devicix, a 
Minneapolis based company that is helping them develop the real product. This company 
is also facilitating NovaScan in development of various protocols necessary to achieve 
the regulatory approval, not only for US, but also for European Union markets. The 
importance of this role has also been discussed in Chapter 2 (literature review). 
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5.6 Contribution of End Users in the Design Stage 
 
Proposition (6) Product design discussions with end users should initiate in early stages 
of development for a successful commercialization. 
 
 
Donald A Norman in his book, the design of everyday things (2002) narrates a 
problem identified by a designer (Name Unknown), 
 
We often know the product too well to envision how people will 
use it and yet we are separated from the end users by multiple layers of 
corporate bureaucracy, marketing, consumer services etc. These people 
believe they know what their [consumers] want and feedback is limited 
by the filters they impose. If you accept the problem definition from 
these outside resources without a personal investigation you would 
design an inferior product regardless of your best intentions. If this 
initial hurdle is overcome you are only half way home.  
 
 
Identifying real end users and holding discussions regarding product and 
technology helps in defining direction for a successful product. It can define the need and 
improve the design of the product simultaneously.  
NovaScan LLC presented their early data to physicians and surgeons and sought 
feedback on the viability of devices on their patented EPET technology. While the 
company wanted to introduce an electrical mammogram, the users defined need for for a 
device that would solve the ‘residual cancer’ problem. That was a discussion that led the 
company to shift its focus to a more need based innovation and commercialization. The 
need analysis revealed a market for the hand held surgical device suggesting an 
opportunity for a successful market launch. 
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Apart from helping in identifying need, the discussions with end users also helped 
the company shape their product. The requirement of the hand held device forced the 
company to shrink the size of technology that could fit into nothing larger than that of an 
electrical tooth brush. 
(Appendix E) 
Repeat meetings and discussions with the surgeons helped them work on form 
and human factors. The surgeons could share issues of using devices in surgical suite . 
This helped in  identifying both ergonomic and technical concerns. The availibilty of 
these inputs from the very early stages of development helped NovaScan in a speedy 
development and elimination of cost of repeated rengineering again and again of the 
functional prototype. When the first functional prototype was developed by NovaScan, it 
had included almost all the consumer led feedbacks already . 
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5.7 Availability of Funds 
 
Proposition (7) Availability and management of funds ensures availability of timely 
resources for commercialization.  
 
NovaScan planned its business and started off as a small startup with self-funding. 
Self-funding or bootstrapping is still the most common and safest approach for startups 
(Zwilling, 2013). Zwilling also recommends accumulation of funds before starting off 
with the business.  
 NovaScan raised the next round of funds from friends and family investments. 
They applied for business plan contests and other business grants. This source is a major 
focus these days due to government initiatives to incentivize research and development. 
In Figure 4.1 of Chapter Four, the timeline and availability of funding resources is 
described. Many startups also use Crowd funding method which is an online fund raising 
strategy. People are requested to make donations, preorder in case of an already 
developed product for some equity or other reward. NovaScan still being in the early 
stage of actual product development did not use this method. Loan is also a way of 
keeping funds in place. NovaScan applied for some short term loans from the local state 
agency. 
 The company had a strong strategic plan for management of resources from the 
very early stages. They generated funding from varied sources recommended by the 
practitioners in the field. This helped company stay afloat even during the slow research 
and development progress stage of commercialization. 
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5.8 Framework of Commercialization 
 
 
Souder and Sherman (1994) used the term concurrent commercialization. They 
used it to describe a situation where the start of the production ramp-up phase and the go-
to-market phase overlap. However, Simula (2012), in a comparison of Business to 
Business commercialization, identifies concurrent commercialization as a much broader 
concept that starts already from the ideation phase. The key point here is that the 
commercialization process does not happen in isolation with product development in a 
startup firm. Like at NovaScan LLC, commercialization strategies are an integral part of 
development work and are well-aligned with the development process, rather than as a 
separate step. For small start-up firms such as NovaScan LLC, this type of 
commercialization is perhaps an easier way to work because there is not a need to 
Figure 5.2 Suggested Framework of commercialization (An integrated scheme with product development) 
(Source: Sheerin S, Patrick T, IATI BioMed Conf 2013(Israel)) 
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communicate between the different organizational units. Naturally, larger, established 
firms such as GE or Phillips need to spend more effort on getting all the relevant 
employees on the same page regarding the new product. 
It is worth mentioning that similar ideas have been presented in the extant 
literature. For instance, Newell et al. (2009) critique the traditional linear innovation 
process and state that most innovations actually do not happen in such a manner. Instead, 
they consider innovation to be a complex, iterative, and interactive process (Newell, 
2009). Several articles also point out that product marketing and product-launch planning 
need to be synchronized and overlaid on top of product development (Copper, 1993; Soni 
& Cohen, 2004).  
According to Nevens et al. (1990), the commercialization process should be 
considered as starting from the point of concept generation and cover all organizational 
functions. Similarly, according to Holt (1983) and Cooper (1993) the planning for 
introducing the product on the market should occur at the same time as the technical 
planning (Simula2012). 
Based on the literature review, and the NovaScan case study, it is suggested that 
commercialization should be seen differently than the traditional linear model described 
in literature. The case revealed that, in reality, it is quite difficult to separate product 
innovation into distinct ideation, development, and commercialization phases. Thus, 
traditional linear models hardly do justice to real product innovation processes. In light of 
this shortcoming,  
The commercialization framework presented in Figure 5.1 draws together the 
theoretical and the empirical findings of this dissertation. Commercialization and product 
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development are processes that work hand in hand and run simultaneously is the main 
idea depicted in the figure.  
The bigger umbrella supporting the commercialization activities through and 
through is the availability of funds. The phase of prototype development, testing and 
evaluation is the lengthiest process in commercialization of a healthcare product 
innovation. It is this phase that seems very critical as cost of developing trial study is very 
high and at the same time very elaborate and time consuming especially for devices or 
technologies in healthcare. (Following the guidelines of the FDA regulatory procedures)  
 
 
 
Sometimes lack of funding results in the difficulty of covering the negative cash 
flow in the early stages of a startup, before their new product or service is bringing in 
revenue from real consumer (Zwilling, 2013).This stage is termed as Valley of Death 
(Figure 5.3). Management of funds, early commercialization strategy and identification 
of the facilitator or strategic alliances early on can help companies keep from falling into 
this and achieve an early recovery in case of a fall (Zwilling, 2013). 
 
Figure 5.3 Valley of Death 
(Source: Zwilling M, 10 Ways For Startups To Survive The Valley Of Death, 2013) 
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Chapter 6 
Conclusions  
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This final chapter describes the study’s contributions to theory and its 
contributions to practitioners. It also discusses the validity, reliability, and limitations of 
this study. Finally, opportunities for future studies are described. 
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6.1 Novel Contributions of this Dissertation 
 
 
This dissertation is a contribution towards new knowledge for innovators, 
researchers, academicians and other practitioners of innovation and commercialization. 
This knowledge covers ways research based small firms developing medical devices can 
move ahead from innovation to a successful path to commercialization. The study 
discussed in this dissertation examines qualitatively commercialization practices of 
NovaScan LLC, a breast cancer detection device company. Through this single case 
study, various performance indicators of the commercialization steps followed by the 
company are identified and findings are presented in the form of theoretical propositions 
and a theoretical framework of commercialization. Extensive literature review and 
analysis contributed to a better understanding of the process of commercialization from 
both healthcare and non-healthcare perspectives. 
A literature gap exists in terms of understanding how the commercialization of 
innovations in technology based industries can determine commercial success or failure 
(Chiesa and Frattini, 2011). The focus of the Chiesa and Frattini study was the non-
healthcare consumer market. They emphasize on further exploration that the industrial 
market needs to be studied more closely. Based on the detailed literature review 
conducted for this dissertation it can be said that there is a research gap in terms of 
understanding how commercialization activities can determine success in the healthcare 
medical device market. This dissertation aims to understand these gaps in the light of the 
actual work in real settings performed by innovators and researchers during the 
commercialization process. Since the dissertation purpose is to build a theory, the 
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findings do not aim to close the gaps. Rather the purpose of this study is to provide a 
theoretical framework based on those gaps that need testing in further studies. 
The desired outcome of any new product development effort is timely 
commercialization of a profitable product (Griffin and Hauser, 1996). Commercialization 
is considered a desired outcome of new product development (NPD). While there is 
commercialization whenever there is a new product, commercialization may not be the 
obvious fate of all new products.  
The study of NovaScan LLC for the purpose of this dissertation revealed several 
important aspects that need attention in the commercialization process. The importance of 
cross-functional teams in the new product process has been documented and discussed 
widely (Nonaka, 1990; Aaby & Discenza, 1993; Hutchings & Knox, 1995; Song, 
Thieme, & Xie, 1998; Kono, 2005; Prebble, Gerrit, & de Groot, 2008). Researchers have 
found that when firms utilize a cross-functional team, they increase the quality of the 
product (Song et al., 1998), the success rate of the project (McDonough III, 2000), the 
success rate of new products (Cooper, 1994; Valle & Avella, 2003), and they also 
improve the launch success of the new product (Kono, 2005).  
However, it takes time, resources, and leadership skills to build consensus 
between different units in  because managers need to navigate between diverse opinions 
and objectives (Song et al., 1998).While these statements have been made in regards to 
the non-healthcare products, the extant literature review and research findings concerning 
NovaScan LLC makes it possible to say that in a setting of medical device innovation and 
commercialization, the process of commercialization has to be synchronized and more 
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integrated. This approach has been suggested in sub section Eight of Chapter Five of this 
dissertation as a framework of commercialization The idea presented is that 
commercialization practices do not happen in a linear non-integrated way, (as 
traditionally considered) in the field of medical device innovations. These 
commercialization practices are synchronized and integrated together from the 
conception of the idea to the time it reaches its end user. This statement is based on the 
observations made at NovaScan LLC and the literature analyzed. 
Ruokolainen (2008) studied a start-up firm in the software industry and noted that 
the first consumer reference is especially important for companies trying to enter a 
competitive business-to-business market for complex products, where it may be 
impossible to convince a potential customer of the product’s value without evidence that 
it functions well in the real world. The importance of testimonials is valid in the case of 
NovaScan LLC as well however in the medical device industry substantial evidence of 
functional parameters is what builds the testimonials. The testimonials from the 
physicians and surgeons paved NovaScan LLC’s path to funding.  
The statement made by Ruokolainen is an important aspect of the software 
industry and can be extended to the medical device industry as well. This has been 
reported in this dissertation as Proposition Three in Chapter Five. The Propositions Two 
and Three of Chapter Five emphasize the importance of both consumers and their 
testimonials. The findings in this study and the analysis of literature helped in framing all 
the seven propositions. These propositions are an effort to fill in the literature gap 
focused on consumers.  
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The literature on product innovation considers the product innovation process to 
be comprised of three phases: a front-end phase, a development phase and a 
commercialization phase (e.g., Buckler, 1997; Koen et al., 2001). This type of linear 
approach with separate activities is embedded in various articles in the NPD literature, 
too (e.g., Cooper, 1996; Khurana & Rosenthal, 1997; Griffin, 1997; Schilling & Hill, 
1998) (Simula 2012).This study represents one of the first attempts to assemble empirical 
data about the commercialization activities of small startup firms in the field of 
developing medical devices in healthcare.  
Jalkala (2009) as reported by Simula (2012) studied the phenomenon of consumer 
reference marketing. She states that, “While [consumer] references are typically 
considered an important marketing and sales tool, the academic literature has paid very 
little attention to the phenomenon”. As evident, the statement is made with respect to 
marketing and sales. Since sales and marketing are an integral part of commercialization 
activities for any technology or product, it can be stated that the same lack of studies 
applies to commercialization. Gaps in the literature have been discussed in detail in 
Chapter Three. The emphasis on consumer references is very limited in the extant 
literature.  
According to Rogers (2003), “the presence of an innovation champion contributes 
to the success of an innovation in an organization”. Identifying such a champion early on 
in the process helps research based organizations to have access to critical resources such 
as licensing, linking to product development agencies, research design, review of various 
protocols, access to industry and opportunities for collaboration and networking. 
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The relevant gap in the literature is that there is no uniform evidence based best 
practice methodology reported in the literature that defines the process of 
commercialization of healthcare medical devices. Since the purpose of this dissertation is 
to build a theory; it does not aim to completely fill this gap identified in the literature. 
The dissertation has developed propositions and a theoretical framework based on 
literature findings and empirical data collected from the NovaScan case study. These 
findings should be tested in future follow up studies. This focus on the identification of 
evidence based commercialization practices will also contribute to the body of 
knowledge in this field. Forthcoming studies can verify the validity of the propositions 
and the theoretical framework developed. If the proposition and theoretical framework 
presented in this dissertation hold true then they may be incorporated in other marketing 
and new product development. Thus, this study is a novel contribution to the attempts to 
assemble empirical data about the commercial activities of small startup firms in the field 
of developing innovative medical devices in healthcare. 
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6.2 Implications and Relevance to Industry 
 
This study aims to fulfill the academic requirements for the PhD dissertation and 
has some practical relevance for practitioners. They may benefit from the case study 
presented here because it can provide some ideas for the commercialization of other 
products (other than breast cancer detection device). 
The propositions presented in Chapter Five, are not intended to prescribe standard 
guidelines. As Numagami (1998) says, “There is only a very slight chance, if any, of 
being able to discover an invariant law that will be useful in suggesting what managers 
should do to adapt to the future course of events” (Simula 2012).  
In addition, because the research is based on a single case study and was not 
carried out from the perspective of the population at large, it would be misleading to 
generalize the findings to any particular population. Therefore, these propositions should 
be interpreted with caution. These propositions need to be studied and verified in future 
research work. However, if the propositions hold true, they can provide some stimulus for 
practitioners to apply them in the future. 
The focus of this study was to emphasize the activities that NovaScan LLC had 
engaged in, since inception of EPET Technology to the development of their first 
prototype and the direction they intend to take in future for developing their final product. 
The propositions of Chapter Five can be considered as the basis for a theoretical approach 
that can improve the chances for the commercial success of a new medical device. These 
propositions will help practitioners to keep focus on some of the evidence based 
successful activities. 
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According to Rogers (2003), “The innovation process does not always begin with 
a perceived problem or need. A considerable degree of serendipity may occur”. While 
Rogers’s statement is accepted here it is also recognized that, sometimes timing plays a 
very critical role as well. Timing in conducting need analysis, timing in writing business 
plans, timings in doing competitor analysis and so on. An understanding of timing may 
play a crucial role in conducting various activities. 
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6.3 Reflections on Research Questions 
 
The main research question “What practices can be identified as the best 
practices engaged in the process of commercialization of a medical device 
innovation?”   
As discussed in the earlier sections, to understand better this main question in context to 
the case study, it was divided it into following parts:  
R1: What activities did technology innovators and researchers perform at NovaScan 
to initiate the process of commercialization?  
R2: What is the evidence that these approaches are successful? 
The single case study presented here in this dissertation and the case analysis of 
that company aimed at providing answers to the above mentioned research questions. In 
addition the propositions presented in Chapter Five and the conceptual framework for a 
more collaborative and integrated commercialization also aimed at providing an answer 
to the questions. 
Any answers to these above mentioned research questions presupposed answers to 
the questions like: what is product innovation? What is commercialization? What defines 
success and failure in innovation and how are they measured? The answers to most of 
these questions were found in the Chapter Three via an extensive literature review. This 
led to find answers to the main research question. The literature review in section 2.1 to 
2.8 and the further discussion of success and failure covered in section 2.16 provide 
answer to the question, “what is the role of success and failure in innovation and how are 
they measured?” The literature review in section 2.13, 2.14 and the discussion in chapter 
5 provided answers to the question, “what is commercialization. Finally, the within case 
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analysis provided answer to the questions, R1: What activities did technology innovators 
and researchers perform at NovaScan to initiate the process of commercialization? And 
R2: What is the evidence that these approaches are successful? 
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6.4 Validity, Reliability and Replicability Issues 
 
 
Qualitative researchers utilize various validation strategies to make their studies 
credible and rigorous (Creswell & Miller, 2000). Credibility for this study was achieved 
using the validation strategies of triangulation, researcher reflexivity and rich observation 
and description. 
The first validity procedure was prolonged engagement in the field (Creswell & Miller, 
2000) or what Merriam (1998) calls "long-term observation".  
 For the purpose of this dissertation, NovaScan LLC was studied for more than 
four years both as an outsider initially and then as an insider later on.  During each of 
these observation procedures, there was consistent contact with the company and its 
progress.  Association with the case study NovaScan LLC for this length of time allowed 
some preliminary findings and then a thorough follow up through observations and 
interviews (Creswell & Miller, 2000).  Therefore, the length of the case study and the 
consistent contact lends credibility to the researcher’s perceptions of this experience. 
In addition to prolonged engagement in the field, another important validity 
procedure of triangulation was used (Creswell, 1998).  Merriam (1998) defines 
triangulation as "using multiple investigators, multiple sources of data, or multiple 
methods to confirm the emerging findings" (p. 204).   
Denzin (1984) identified four types of triangulation: Data source triangulation, 
when the researcher looks for the data to remain the same in different contexts; 
Investigator triangulation, when several investigators examine the same phenomenon; 
Theory triangulation, when investigators with different viewpoints interpret the same 
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results; and Methodological triangulation, when one approach is followed by another, to 
increase confidence in the interpretation. 
Data triangulation method was used (Creswell & Miller, 2000) especially on three 
forms of data: observations, unstructured and informal interviews, and documents. The 
informal interviews were conducted with several participants (Creswell & Miller, 2000) 
of NovaScan LLC.  The process of triangulation was used to seek convergence in the data 
and to confirm or disconfirm emerging categories and themes (Creswell & Miller, 2000). 
Categories or themes that emerged in the within-case analysis were compared with 
literature findings.  If a category did not hold true across cases and literature, it was 
generally deemed to be unreliable. The outcomes are presented in the form of 
propositions and that forms a theory basis for future research studies.  
Finally, the validity procedure of thick description is used. This procedure of 
writing gives the reader a sense of being there and to capture the essence of the 
experience (Creswell & Miller, 2000).  This is an important feature in case study design 
that is presented to the reader through the case description.   
Joppe (2000) defines reliability as: “...The extent to which results are consistent 
over time and an accurate representation of the total population under study is referred to 
as reliability and if the results of a study can be reproduced under a similar methodology, 
then the research instrument is considered to be reliable”. Embodied in this citation is the 
idea of replicability or repeatability of results or observations.  
Reliability and replicability are clearly problematic in case studies. Numagami 
(1997) points out that it is hard to meet the reliability criterion in its most literal sense 
because Whatever documentation a researcher devises, the ultimate quality of the 
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research findings from qualitative approaches ought to vary with his or her social and 
conceptual skills because what can be obtained from, for example, interviewing, seems to 
be dependent more on human and contextual factors of the particular research project 
than is the case with other data gathering techniques .  
However, the same dilemma is also present in surveys. According to Numagami (1998), a 
language system evolves over time and the wording used in questionnaires may 
propagate different meanings, too. 
In any event, as Remenyi at al. (1998) point out, with a phenomenologist approach it can 
be argued that “all situations and organizations are different and thus the same results 
cannot ever be obtained again, 
Because so much depends on the researcher's personality and approach, a case study is 
difficult to repeat. 
Lincoln and Guba (1985) states that: "Since there can be no validity without 
reliability, a demonstration of the former [validity] is sufficient to establish the latter 
[reliability]”. 
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6.5 Limitations of the Present Study 
 
Commercialization can be seen as a complex phenomenon (Simula 2012). One 
could enter into an endless conceptual debate about whether commercialization should be 
considered as a sub-category of marketing or as a sub-category of the new product 
development process instead of defining it as a separate concept. As there are hardly any 
exact concepts in literature, it is impossible to provide a solid argumentation against these 
kinds of claims. Empirical material is used in this dissertation to support the argument for 
considering commercialization differently. 
There can be several sources of bias in case studies. Jones and Stevens (1999) 
argue that an analysis of failure probably provides a more useful lesson for managing 
innovation. The failure part was discussed in the literature review. This case, however, 
focuses primarily on success, which naturally can be seen as a bias in this study. 
Rogers (2003) says, “Serendipity and accidental aspects of the innovation-
development process are unlikely to be fully reported in research publications written by 
the inventors and researchers.” In this study while full attention to detail was given and 
the steps of innovations and commercialization at NovaScan LLC were studied in stages 
of development to eliminate the possibility of losing any piece of information. However, 
it would be unrealistic to ignore the possibility of missing and failing to report at least 
some such information. 
Another cause of concern can be selection of number of cases to be included in 
the study. This dissertation is based on a single case study. The study of innovations and 
commercialization in the light of more complex situations and at more than one case 
study may have resulted in a different output.* 
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Eisenhardt and Graebner (2007) explains that, 
  
Multiple-case researchers retain only the relationships that are 
replicated across most or all of the cases. Since there are typically 
fewer of these relationships than there are details in a richly observed 
single case, the resulting theory is often more parsimonious (and also 
more robust and generalizable) (Eisenhardt and Graebner , 2007). 
 
More cases could have been included by approaching additional firms. However, 
with case studies the typical criteria regarding sample size is irrelevant (Yin, 1994). In 
other words, adding a few additional cases does not increase the statistical relevance of 
the study. Thus, the choice of a single case study seemed adequate.  
The amount of required observation data and interviews are also questions to 
which there is no exact answer and different opinions exist in the academic literature. The 
guiding principle is to gather enough information so that theoretical saturation** is 
achieved (Johnson, 2002). Another limitation of this dissertation is the number of 
participants in this study. NovaScan had a total of six employees including full time and 
part time. Had there been more people working at NovaScan LLC, more informants 
would have contributed to the study and would have provided support to the case more 
strongly. But at the same time, the amount of time spent as a participant observer 
provided a deeper understanding of both relevant and irrelevant details pertaining to this 
case, adding more insight as such.  
 
 
*    It could have been a never-ending story; there are numerous firms with successful products. 
** The issue is impossible to verify in reality. The point of saturation is also always difficult to determine objectively. 
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6.6 Suggestions for Future Research 
 
 
There has to be a better way – find it. - Thomas Edison 
 
 
Theory validation follows theory building (Simula 2012). The qualitative method 
was suitable for this study, but quantitative research could take place next in order to test 
whether or not the propositions presented in Chapter Five are valid. 
This study was only able to study innovation and commercialization practices of a 
single case, NovaScan LLC. The company is currently in the process of conducting pilot 
trial study after establishing and conducting the proof of concept study. It is also 
preparing for the next Pivotal trial for FDA approval. A next study would be to continue 
the investigation until the market launch of their hand held device for detection of cancer 
during surgery. That future study would be of more in-depth in nature and the researcher 
would be able to follow the whole life cycle of that product. 
For the purpose of this dissertation the regulatory procedures and the role of 
patents are not included in the process of commercialization. Regulatory procedures 
require consideration from the early stages of inception, get more attention when 
conducting studies on real humans, and even more so for getting FDA approvals. These 
successes of such studies also attract venture investments. The future study can include 
these aspects for a more thorough investigation. 
Another source of innovation can be the number of patents. Bound et al.(1984) 
demonstrated that the number of patents increases at a rate that is less than proportional 
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to firm size and other authors; Acs and Audretsch (1987, 1991), confirm the same results 
using the number of innovation as output variable. Henderson and Cockburn (1996), 
Mansfield, (1980) showed that larger firms have in some cases an advantage in 
innovation.   
In the field of innovations and commercialization, patents also play an important 
role. However, for the purpose and scope of this study they are not included in the 
research questions of this dissertation and its boundaries. However it is recommended 
that this aspect be applied in future research projects. 
 
 
Cui et al. (2011) suggest avenues for future research related to the launch of new products 
and states that, 
 
The important role of managers’ perception of market conditions also 
highlights the need to study the behavior of new product managers. 
Perception of market conditions is formed within the context of the 
managers’ individual knowledge and experience, and influenced by 
their personality traits and management style. (Cui et al., 2011) 
 
 
The same idea could be applied to study of innovation and commercialization as 
well. At NovaScan LLC, the inventor was the chief science officer, also performed 
responsibilities of the chief executive officer (CEO) and was also chairman of the board. 
He also played the role of a new product manager in the company. It is also 
recommended for future research to study the role of innovator who plays different roles 
in the process of commercialization. 
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APPENDIX B 
Definition of Innovations in various Literatures 
 
Afuah 1998  
Innovation is the use of new knowledge to offer a new product or service that customers 
want. It is invention + commercialization. 
 
Betje 1998  
Innovations are new things applied in the business of producing, distributing and 
consuming products or services 
 
Boer and During 2011  
Innovation is the creation of new product-market-technology-organization-combination 
 
Bradbury 1989  
Innovation is therefore a creatively initiated process which is then developed and 
progressed to a definable goal by the application of further creativity allied to logical 
analysis and work organization in which the creative element continually introduces 
'change' as a 'horizontal shift' in the logical progression of the chain 
 
Crawford and Di Benedetto 2006  
Innovation refers to the overall process whereby an invention is transformed into a 
commercial product that can be sold profitably. 
 
Crossan and Apaydin 2010  
Innovation is production or adoption, assimilation, and exploitation of a value-added 
novelty in economic and social spheres; renewal and enlargement of products, services, 
and markets; development of new methods of production; and establishment of new 
management systems. It is both a process and an outcome 
 
Dodgson 2000  
Innovation includes the scientific, technological, organizational, financial, and business 
activities leading to the commercial introduction of a new (or improved) product or new 
(or improved) production process or equipment. 
 
Freeman and Soete 1997  
The first commercial application or production of a new process or product 
 
Hult 1983  
Innovation is a process which covers the use of knowledge or relevant information for 
creation and introduction of something that is new and useful 
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Knight 1967 
An innovation is the adoption of a change which is new to an organization and the 
relevant environment 
 
Morton 1971  
Technological innovation is the process of perception or generation of relevant science 
and its transformation into new and improved products and services for which people are 
willing to pay 
 
Myers and Marquis 1969  
Innovation is not a single action but a totol process of interrelated sub processes. It is not 
just the conception of a new idea, nor the invention of a new device, nor the development 
of a new market. The process is all these things acting in an integrated fashion. 
 
Narayanan 2001 
Innovation refers both to the output and the process of arriving at a technologically 
feasible solution to a problem triggered by a technological opportunity or customer need. 
 
Padmore & et. al. 1998  
An innovation is any change in inputs, methods, or outputs which improves the 
commercial position of a firm and that is new to the firm's operating market  
 
Parker 1980 
Innovation involves the birth of a new idea, often an invention, together with its 
successful progression to a new material, process, product or system. It implies a 
discontinuity and a radical change in the way a company should be managed. 
 
Pessemier 1977 
The act of introducing something new or novel (making an addition to the things 
previously available) 
 
Robertson 1967 
Innovation has been defined as a process whereby a new thought, behavior, or thing is 
conceived of and brought into reality 
 
Rogers 2003  
Innovation is an idea, practice, or object that is perceived as new by an individual or other 
unit of adoption 
 
Rogers and Shoemaker 1971  
An innovation is an idea, practice, or object perceived as new by an individual 
 
Schumpeter 1939  
Setting up a new production function 
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Scott and Bruce 1994  
Innovation is a process involving both the generation and implementation of ideas 
 
Souder 1987  
Innovation refers to a high-risk idea that is new to the sponsoring organization, and which 
the organization believes has high profit potential or other favorable commercial impacts 
for them. 
 
Trott 2002  
Innovation = theoretical conception + technical invention + commercial exploitation 
 
Trott 2002  
Innovation is the management of all the activities involved in the process of idea 
generation, technology development, manufacturing and marketing of a new (or 
improved) product or manufacturing process or equipment 
 
Van de Ven 1986 Innovation has been defined as the development and implementation of 
new ideas by people who over time engage in transactions with other within an 
institutional context 
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APPENDIX C      
Laws of Technology Transfer 
Stevenson-Wydler Technology Innovation 
Act 1980 (Public Law 96-480) 
 
• Focused on dissemination of information. 
• Required Federal laboratories to take an active role in technical cooperation 
• Established Offices of Research and Technology Application (ORTA) at major Federal laboratories.  
At many laboratories and agencies, these are simply called technology transfer offices. 
• Established the Center for the Utilization of Federal Technology (in the National Technical 
Information Service) 
Bayh-Dole Act of 1980 (Public Law 
96-517) 
 
• Permitted universities, non-profit organizations, and small businesses to obtain title to 
inventions developed with governmental support. 
• Allowed Government owned, Government operated (GOGO) laboratories to grant exclusive 
licenses to patents. 
Trademark Clarification Act of 1984 
(Public Law 98 620) 
• Primarily pertains to non-Department of the Interior laboratories, such as Department of Energy 
National laboratories (many of which are Government-owned, Contractor-operated-GOCOs). 
• Permitted decisions to be made at the laboratory level in Government owned, Contractor operated 
(GOCO) laboratories regarding the awarding of licenses for patents. 
• Permitted contractors to receive patent royalties for use in R&D, awards, or for education  
• Permitted private companies, regardless of size, to obtain exclusive licenses. 
• Permitted laboratories run by universities and nonprofit institutions to retain title to inventions 
within limitations. 
Federal Technology Transfer Act (1986) • Made technology transfer a responsibility of all Federal laboratory scientists and engineers. 
• Mandated that technology transfer responsibility be considered in Federal laboratory employee 
performance evaluations.   
• Defined a new kind of collaborative agreement to encourage Federal laboratory and private sector 
partnerships: the Cooperative Research and Development Agreement (CRADA).  
• Established royalty sharing for Federal inventors (15% minimum) and set up a reward system for 
other innovators. 
• Chartered the Federal Laboratory Consortium for Technology Transfer (FLC). 
• Provided specific requirements, incentives and authorities for the Federal laboratories. 
• Empowered each agency to give the director of GOGO laboratories authority to enter into 
cooperative R&D agreements (CRADAs) and negotiate licensing agreements with streamlined 
headquarters review. 
• Allowed laboratories to make advance agreements with large and small companies on title and 
license to inventions resulting from Cooperative R&D Agreements (CRADAs) with government 
laboratories. 
• Allowed directors of GOGO laboratories to negotiate licensing agreements for inventions made at 
their laboratories. 
• Provided for the exchange of GOGO laboratory personnel, services, and equipment with research 
partners. 
• Made it possible to grant and waive rights to GOGO laboratory inventions and intellectual property. 
Executive Orders 12591 and 12618 
(1987): Facilitating Access to Science and 
Technology 
 
• Promoted the commercialization of Federal science and technology. 
Omnibus Trade and Competitiveness Act 
of 1988 (Public Law 100 418) 
• Placed emphasis on the need for public/private cooperation to assuring full use of results of 
research. 
• Established centers for transferring manufacturing technology. 
• Established Industrial Extension Services within states and an information clearinghouse on 
successful state and local technology programs. 
• Changed the name of the National Bureau of Standards to the National Institute of Standards and 
Technology and broadened its technology transfer role. 
• Extended royalty payment requirements to non-government employees of Federal laboratories. 
• Authorized Training Technology Transfer centers administered by the Department of Education. 
National Competitiveness Technology 
Transfer Act 1989 (Public Law 101-189) 
• Granted GOCO laboratories opportunities to enter into CRADAs and other activities with 
universities and private industry, in essentially the same ways as highlighted under the Federal 
Technology Transfer Act of 1986 for GOGOs. 
• Allowed information and innovations brought into, and created through, CRADAs to be protected 
from disclosure. 
• Provided a technology transfer mission for the nuclear weapons laboratories. 
American Technology Preeminence Act 
1991 (Public Law 102 245) 
 
   
 
• Extended the Federal Laboratory Consortium (FLC) mandate, removed FLC responsibility for 
conducting a grant program, and required the inclusion of the results of an independent annual audit 
in the FLC Annual Report to Congress and the President. 
• Included intellectual property as a potential contribution under CRADAs 
• Required the Secretary of Commerce to report on the advisability of authorizing a new form of 
CRADA that permits Federal contributions of funds. 
• Allowed laboratory directors to give excess equipment to educational institutions and non-profit 
organizations as a gift. 
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APPENDIX C        
 Source: Technology Transfer Handbook for the U.S. Geological Survey2003 
The National Technology Transfer and 
Advancement Act of 1996 
 
• Guarantees a Cooperative Research and Development Agreement (CRADA) industrial partner the 
option to choose an exclusive license to the resulting invention in a field-of-use. 
• Clarifies that agencies may use royalties to hire temporary personnel to assist in CRADA or related 
projects. 
• Gives first $2,000 of royalty income to the inventors and increases an inventor's maximum royalty 
award to $150,000 per year. 
• Allows laboratories to use royalties for related research in the laboratory. 
• Refines the laws concerning excess scientific equipment 
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APPENDIX D 
 
Informal discussion and General questions 
 
What does commercialization mean? What kind of activities and critical events happened 
since inception at NovaScan LLC? 
What kinds of problems were encountered since inception? 
Why do you think the technology and the product based on this technology will be 
successful? 
What kind of benefits the product provide for consumers 
Who are the consumers for NovaScan’s products? 
What is the most difficult thing for NovaScan to commercialize its products? 
What do surgeons feel about the EPET Technology? 
What was the consumer’s role during the product development? 
What kind of problems you encountered while trying to sell the concept of electrical 
mammogram to the surgeons 
Did you take notes and carry further discussions based on surgeon’s feedback? 
Have you seen cases where a product, which seems like a failure right after the 
introduction has become successful later on? 
Did the product change from the original during the development? 
Is the product customized based on customer requirements? 
What kinds of criteria were considered before a decision to develop FastPathTM surgical 
probe? 
Who were the main actors during that?  
Was it easy to convince consumers that the product will work as promised? 
Could you please describe briefly the market and special characteristics of it? 
Was there enough funding available for the research and prototype development? 
What were the sources of funding? 
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How did you come up with the name for the product and what were the things related to 
that? 
What do you think are the most important activities that ensure a product to become 
successful? 
Is there any internal competition between this product and other products? 
Are there any strategic partners? What are their roles? 
Who decides about the product development changes? 
What will be the main main things behind the success of commercialization of surgical 
probe? 
When do you expect the launch? 
Do you monitor the technical readiness on a regular basis? 
What kind of regulatory procedures the surgical probe will have to undergo? 
How expensive would these regulatory approvals will be? 
When will the company be ready for the FDA trials? 
The strategic alliances that company made with Aurora and Devicix, how productive is it 
for NovaScan LLC 
What does the term “commercialization” means at NovaScan LLC? 
Is commercialization process mapped or described at NovaScan LLC?  
o IF YES: Is it stand alone process or a part of other main process? 
o IF NO: Should it be perhaps describe? 
How many times do you follow with you consumers for product feedback and so on? 
APPENDIX D   
181 
 
APPENDIX E 
 
 
 
Case Product (1) Electrical Mammogram 
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Case Product (2) FastPathTM surgical probe  
 
APPENDIX E 
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APPENDIX F 
 
This list describes several factors that may need consideration before market launch of a 
product. The list is just illustrative. Some of the items are not necessarily needed and 
there can be items that are missing. (This information is based on the extant literature and 
author’s own experience.) 
- Product (and service) brochure (printed and online versions) describing features 
function and benefits. 
- Audience specific data sheets with more technical description of a product 
- Posters / banners 
- Name & branding 
- White paper(s) / leaflet(s) 
- Exhibition stands and demos (+ company specific marketing material, handouts, 
gifts, takeaways etc.) 
- Review articles by magazines, newspapers analysts etc. 
- Customer testimonials 
- Letter/certificate of compliance (proof that a product meets standards, regulations, 
directives etc.) 
- Video clips about a product and its usage 
- Visual aids i.e. pictures, 3D images, virtual tours/demos etc. 
- Roadmap  
- Product specific website (where all the above mentioned items can be viewed or 
downloaded) 
- Samples (either the product samples or test samples i.e. output of usage of a 
product)  
- Distribution plan and channel selection 
- Tradeshow, event and seminar plan & calendar 
- PR activities (press tour / analyst coverage) 
- Action plan for social media presence 
- Non-disclosure agreements 
- Licensing agreements 
- Prototypes or physical mock-ups if a product is still under development 
- Packaging & artwork 
- Press release material 
- Press tour plans 
- Webinars/seminars 
- blog pages / on-line forums 
- Advertising material & campaigns 
- Sales process descriptions 
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APPENDIX G 
Literature findings-Reasons of commercialization failure 
  
Ignored or misinterpreted market research Calantone  and Cooper (1981), Kotler and 
Keller 
 
Misunderstanding of customer needs Cooper  (1976),  Jain  (2001),  Leadbeater  
(2006), 
    
Small size of potential market Jain (2001) 
Changing market requirements not understood Parker and Mainelli (2001) 
Competitors’ aggressive actions Kotler and Keller (2009) 
Incorrect positioning Crawford (1977), Kotler and Keller (2009), 
Rehn & Lindahl (2011) 
   
Stronger competition than expected Cooper (1975) 
No clear differentiation Jain (2001) 
Market newness to the firm Calantone  and Cooper (1981), Kotler and 
Keller 
 
Product newness to the market Calantone and Cooper (1979) 
Ineffective  advertising  or  lack  of  selling  and promotion 
resources 
Calantone  and Cooper (1979), Kotler and 
Keller 
     
Misdirected marketing efforts Cooper (1975), Lee and O’Connor (2003a) 
Insufficient   distribution   support   or   lack   of channel 
partner motivation and incentives 
Kotler  and Keller  (2009);  Hill (1988),  
Berggren 
      
 
Product focus crowded on customer  needs Rackham (1998) 
Prototyping neglected Rehn & Lindahl (2011) 
Poor  product  launch  advertising  strategy  and 
communication with customers 
Lee and O’Connor (2003b) 
Special characteristics of culture and market not understood Sheth and Ram (1987) 
Unexpectedly high development costs Crawford (1977), Kotler and Keller (2009) 
Low return on investment Jain (2001) 
Wrong price Cooper (1975), Crawford (1977), 
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No differential advantage Calantone and Cooper (1979) 
Late in the market Jain (2001) 
Too early in undeveloped market Grayson (1984), Jain (2001) 
Timing failure Udell and Hignite (2007) 
Inadequate selling efforts Calantone and Cooper (1979) 
Lack of network effect 
Lee  and  O’Connor   (2003a),   Rehn  &  Lindahl 
(2011) 
Lack of product uniqueness or superiority Cooper (1975), Crawford (1977) 
Poor design or poor prototype testing Jain (2001), Calantone and Cooper (1979) 
Product   not  working   correctly   or  otherwise flawed 
Cooper  (1975),  Crawford   (1977),  Jain  (2001), 
Folkes  and  Kotsos  (1986),  Calantone  and  
Cooper (1979), Rehn & Lindahl (2011) 
Bet on the wrong technology Carroll and Mui (2008) 
The newness of production process Mishra et al. (1996) 
Lack of organizational support 
Grayson   (1984),   Crawford   and   Di   Benedetto 
(2003), Jain (2001), Rackham (1998), Calantone 
and Cooper (1979) 
Lack of R&D resources and skills Calantone and Cooper (1979) 
Enthusiasm crowded on facts 
Crawford (1977), (Grayson(1984),   Rehn   & 
Lindahl (2011) 
Product lacked a champion Crawford (1977) 
Poor fit with the organizational culture Dipak Jain (2001) 
Company politics 
Grayson   (1984),   Crawford   (1977),   Jones   and 
Stevens (1999) 
Lack of sharing and using market information 
Crawford   (1977),   Hill   (1988),   Calantone   and 
Cooper (1979) 
Management losing course of action 
Grayson  (1984),  Boulding  et al. (1997),  Carroll 
and Mui (2008), Biaylogorsky et al. (2006) 
"Sliding to failure” i.e. the series of decisions that slowly pushed 
the project towards a slide and that accelerated until failure was 
inevitable. Projects might thus slide rather than fall into failure — 
muddle up in a manifold of ways. 
Rehn & Lindahl (2011) 
Companies  trapped  in their  own  thinking  and traditions 
Leadbeater (2006),  Dundas    and    Richardson 
(1980) 
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